

Index

ACCESS DENIAL

To essential facility, as anticompetitive conduct under Section 2 of Sherman Act, § 6:8

ACCOUNTABLE CARE ORGANIZATION SUMMIT

A Common Goal: The U.S. Federal Trade Commission's Healthcare Enforcement Program and its Implications for ACOs, text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Summit Preconference (June 17, 2015), **App. E244**

Antitrust Enforcement in Health Care: Proscription, Not Prescription, text of remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC, before the Fifth National Summit (June 19, 2014), **App. E232**

ACGM, INC.

Advisory opinion, **App. D45**

ACQUISITIONS

Mergers (this index)

ADMINISTRATIVE COMPLAINT

Edwards Lifesciences Corp. and JenaValve Technology, Inc, in matter of, **App.N30**

Lawsuits, **App. N17**

Matter of GTCR BC Holdings, LLC and Surmodics, Inc

FTC Matter/File Number 241 0095, Docket Number 9440, **App. N24**

ADVANCED PRACTICE NURSING

Florida House of Representatives, FTC letter concerning regulation of advanced registered nurse practitioners, **App. D140**

ADVANCED PRACTICE NURSING

—Cont'd

FTC advocacy letter to Veterans Administration, restrictions (July 25, 2016), **App. D188**

FTC collaborative practice agreements between advanced practice registered nurses and physicians, **App. D152**

FTC Executive Summary, "Policy Perspectives: Competition and Regulation of Advanced Practice Nurses" (Mar. 2014), **App. E229**

Kentucky State Senate, FTC letter concerning bill relating to advanced practice registered nurses scope of practice, **App. D150**

Letter from Office of Policy Planning Acting Director Clarke Edwards to Senator Juan Barnett Concerning Mississippi H.B. 1057 to Address the Practice of, registered nurses (January 25, 2026), **App. F15**

Missouri House of Representatives, FTC Staff advocacy letter regarding advanced practice registered nurses, **App. D169**

South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**

Texas State Senate, FTC letter concerning regulation of advanced registered nurse practitioners, **App. D142**

West Virginia Senate, FTC Staff Advocacy letter concerning placing regulation of advanced practice registered nurse under State Board of Medicine and

**ADVANCED PRACTICE NURSING
—Cont'd**

Osteopathy (Feb. 10, 2016),
App. D181

ADVERTISING

Clinic advertising, FTC staff letter to
Massachusetts Department of
Public Health concerning (Sept.
27, 2007), **App. D120**

Limitations on, ethical restraints,
§ 24:6

ADVISORY OPINIONS

ACGM, Inc., **App. D45**

Alaska House of Representatives,
physician joint negotiation stat-
ute (Jan. 18, 2002), **App. D92**

Alliance of Independent Medical Ser-
vices, LLC (Dec. 22, 1997),
App. D80

Alpena Public Schools (June 16,
2006), **App. D114**

American Dental Association (Aug.
26, 1985), **App. D15**

American Dental Association (Feb.
15, 1990), **App. D28**

American Intra-Ocular Implant Soci-
ety, **App. D17**

American Medical Association
(March 26, 1996), **App. D62**

American Medical Association and
Chicago Medical Society, **App.
D42**

American Podiatry Association (Aug.
18, 1983), **App. D4**

American Podiatry Association
(March 13, 1984), **App. D7**

Arkansas Children's Hospital (March
13, 2003), **App. D100**

Associates in Neurology (Aug. 13,
1998), **App. D83**

Association of Quality Health Care,
App. D22

Attorney General of Montana regard-
ing any-willing-provider laws,
App. D36

Attorney General of North Dakota
regarding cooperative arrange-
ments among hospitals, **App.
D37**

ADVISORY OPINIONS—Cont'd

Bay Area Preferred Physicians, **App.
D104**

BJC Health System (Nov. 9, 1999),
App. D87

Business Health Companies, Inc.
(Oct. 19, 1996), **App. D66**

(Oct. 18, 1996), **App. D72**

California All Health, **App. D52**

California Managed Imaging Medical
Group, Inc., **App. D40**

California Senate regarding any-will-
ing-provider laws, **App. D33**

Central Texas Medical Group (Sept.
28, 1995), **App. D58**

Columbine Family Health Center
(Nov. 89, 1995), **App. D59**

Columbus Hospital (June 28, 1996),
App. D65

Community Hospital, Inc. (Dec. 22,
1997), **App. D79**

Competition law and policy, prospec-
tive guidance FTC advisory
opinions (June 26, 2002), **App.
E110**

Connecticut Hospital Association
(Dec. 20, 2001), **App. D91**

District of Columbia Corporation
Counsel, **App. D88**

Dunlap Memorial Hospital, FTC staff
advisory opinion to (Jan. 6,
2004), **App. D105**

Eastern Ohio Physicians Organiza-
tion, Inc. (Sept. 28, 1995), **App.
D57**

Elmore Community Hospital and
Community Hospital, **App. D53**

Equitable Life Assurance Society of
the United States, **App. D21**

Erlanger Medical Center and Memo-
rial Hospital, **App. D51**

First Look, LLC (June 19, 1997),
App. D77

Foundation for the Accreditation of
Hematopoietic Cell Therapy
(Apr. 17, 1997), **App. D74**

FTC

generally, § 10:7, **App. B5, App. D**
see also other entries throughout
this topic

INDEX

ADVISORY OPINIONS—Cont'd

Generic Pharmaceutical Association
(Aug. 8, 2012), **App. D154**
Gilbert M. Frimet, **App. D8**
Greater Rochester Independent
Practice Association (Sept. 17,
2007), **App. D119**
Harvard Vanguard Medical Associ-
ates, Inc. (Dec. 18, 2001), **App.**
D90
Health Care Management Associates,
App. D3
Hematology/Oncology Care Special-
ists of Western Pennsylvania,
P.C. (Sept. 21, 1995), **App. D56**
Henry County Memorial Hospital
(Apr. 10, 1997), **App. D76**
Intracorp, **App. D26**
Kaiser Foundation Health Plan (Feb.
13, 2008), **App. D122**
Kitsap Physicians Service (March 26,
1984), **App. D9**
Kitsap Physicians Service (May 22,
1984), **App. D11**
Louisiana Health Care Association,
App. D2
Lynch, Patrick C. (Rhode Island
Attorney General), FTC staff
letter to (Apr. 8, 2004), **App.**
D106
Maryland Medical Eye Associates,
App. D25
Massachusetts Department of Public
Health, FTC staff letter concern-
ing clinic advertising (Sept. 27,
2007), **App. D120**
Mayo Medical Laboratories (July 17,
1996), **App. D63**
Medical Group Management
Association, staff advisory
opinion to, **App. D103**
Medical Society of the County of
Erie, **App. D6**
MedSouth, Inc. (Feb. 19, 2002), **App.**
D94
MedSouth, Inc., FTC staff follow-up
letter (June 18, 2007) to 2002
advisory opinion, **App. D118**
Mesa County Physician Independent
Practice Association (Nov. 6,

ADVISORY OPINIONS—Cont'd

1997), **App. D78A**
Michael A. Dunccheon, **App. D20**
Michael D. McNeely, Assistant
Director, Bureau of Competi-
tion, to Clifton E. Johnson, **App.**
D44
Missouri Board of Chiropractic
Examiners regarding free or
discounted services, **App. D35**
Mobile Health Resources, LLC (Jan.
23, 1997), **App. D69**
Montana Deaconess Medical Center
(June 28, 1996), **App. D65**
Montana House of Representatives
involving denturists, **App. D34**
National Capital Society of Plastic
and Reconstructive Surgeons
(Apr. 23, 1991), **App. D30**
New Hampshire Senate regarding
any-willing-provider laws, **App.**
D32
New Jersey Pharmacists Association
(Aug. 12, 1997), **App. D78**
North Carolina Chiropractic Associa-
tion, **App. D5**
Northeast Pharmacy Service
Corporation (July 27, 2000),
App. D89
North Mississippi Health Services
(Oct. 3, 1996), **App. D71**
(Jan. 7, 1998), **App. D81**
(Aug. 16, 2005), **App. D112**
North Ottawa Community Hospital
(Oct. 22, 1996), **App. D73**
North Texas Chapter, American Col-
lege of Surgeons, **App. D18**
Northwestern Nevada Orthopaedic
Surgery Alliance, **App. D54**
Oakland Physician Network, **App.**
D50
Ohio Ambulance Network, Inc. (Jan.
23, 1997), **App. D68**
Orange Pharmacy Equitable Network
(May 19, 1999), **App. D86**
Otolaryngology Specialty Providers
of Georgia, **App. D55**
Pacific International Health, **App.**
D23
Palmetto Dental Alliance, **App. D48**

ADVISORY OPINIONS—Cont’d

Pan American Management Associates, **App. D27**
 Passaic County Medical Society, **App. D19**
 Peer Review Organizations of Ohio Foundation, **App. D10**
 Phoenix Medical Network, Inc. (May 19, 1998), **App. D82**
 Physician IPA that sponsors a PPO, **App. D31**
 Presentation Health System, **App. D41**
 PriMed Physicians (Feb. 6, 2003), **App. D98**
 Private Healthcare Systems, **App. D16**
 Rhode Island Attorney General (Patrick C. Lynch), FTC staff letter to (Apr. 8, 2004), **App. D106**
 Rocky Mountain Cardiovascular Affiliates, **App. D49**
 Senator Orrin G. Hatch regarding hospital mergers, **App. D38**
 Southeast Managed Care, Inc., **App. D46**
 Southern Arizona Therapy Network, Inc. (Dec. 7, 1995), **App. D60**
 Southwest Florida Oral Surgery Associates (Dec. 2, 1996), **App. D67**
 Speech entitled “Overview of Advisory Opinion Process at FTC,” **App. E74**
 Staff letter to State of Washington House of Representatives concerning physician joint negotiation statute (Feb. 8, 2002), **App. D93**
 Statement Regarding Physician Agreements to Control Medical Prepayment Plans, **App. D1**
 Stevens Hospital, staff advisory opinion to (Apr. 18, 2005), **App. D110**
 St. John’s Health System (Sept. 13, 2006), **App. D115**
 Suburban Health Organization, Inc., FTC staff advisory opinion to (March 28, 2006), **App. D113**

ADVISORY OPINIONS—Cont’d

Suffolk County Dental Society, **App. D47**
 Tarrant County Medical Society (July 11, 1984), **App. D13**
 Tarrant County Medical Society (May 25, 1984), **App. D12**
 Texas House of Representatives Concerning Joint Negotiations by Physicians (May 13, 1999), **App. D85**
 TriState Health Partners, FTC letter not to recommend challenge of proposed “clinical integration” of members’ provision of health care services (Apr. 13, 2009), **App. D127**
 URONET of Louisiana, LLC (Jan. 23, 1996), **App. D61**
 Utah Society of Oral and Maxillofacial Surgeons, **App. D14**
 Valley Baptist Medical Center (March 13, 2003), **App. D99**
 Valley Baptist Medical Center (Sept. 19, 1996), **App. D70**
 Views on HMO Exclusive Contracts, **App. D24**
 Viquist and Pitt Country Memorial Hospital (Mar. 8, 2002), **App. D96**
 Washington House of Representatives, physician joint negotiation statute (Feb. 8, 2002), **App. D93**
 Wesley Health Center, Inc. (Apr. 29, 1999), **App. D84**
 Wichita, Kansas, Chamber of Commerce, **App. D29**
 William W. Backus Hospital (June 11, 1996), **App. D64**
 Yellowstone Physicians, LLC (May 14, 1997), **App. D75**

AFFORDABLE CARE ACT

Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks of Bill Baer, Assistant Attorney General, before the New Health Care Industry Conference (Nov. 15, 2015), **App. E248**
 Mergers, analyzing hospital, § 15:22

INDEX

AFFORDABLE CARE ACT

—Cont'd

Respecting proposed regulations implementing, statement by FTC Commissioner, **App. E188**

AGREEMENTS

Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414, **App. N8**

Bid-rigging agreements, under Section 1, Sherman Act, § 4:5

Business Review Letter to CEO Roundtable on clinical trial agreements for cancer treatments (Sept. 28, 2008), **App. C101**

Employee non-compete agreements, ethical restraints, § 18:4

Exclusionary Dealing Agreements (Hospital/Physician) (this index)

Horizontal Agreements (this index)

Market-Allocation Agreements (this index)

Participation agreements between providers and payers, health plan market power, § 21:3

Price-Fixing Agreements (this index)

Reciprocal dealing agreements as vertical agreements under Section 1 of Sherman Act, § 5:8

Sherman Act Section 1 violations generally, § 3:2 to 3:6
see also specific types of agreements

capacity to conspire, § 3:5

conspiracy in fact, § 3:6

Vertical Agreements (this index)

“A HEALTH CARE CHECK ON COPAS; ASSESSING THE IMPACT OF CERTIFICATES OF PUBLIC ADVANTAGE IN HEALTH CARE MARKETS” (JUNE 18, 2019)

Joseph J. Simons, remarks, FTC workshop, **App. E268**

ALASKA HOUSE OF REPRESENTATIVES

Advisory opinions, physician joint negotiation statute (Jan. 18,

ALASKA HOUSE OF

REPRESENTATIVES—Cont'd

2002), **App. D92**

Certificate-of-need laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D194**

Federal Trade Commission prepared statement concerning certificate of need (Feb. 15, 2008), **App. E159**

Telehealth services, FTC Advocacy letter to State Legislature concerning (Mar. 25, 2016), **App. D184**

ALASKA SENATE

Certificate-of-need laws and Bill 62. FTC Statement (Feb. 6, 2018), **App. D197**

Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E256**

ALLERGY & ASTHMA CONSULTANTS, INC.

Business review letters (April 24, 1996), **App. C66**

ALLIANCE OF INDEPENDENT MEDICAL SERVICES, LLC

Advisory opinions (Dec. 22, 1997), **App. D80**

ALLIED COLON AND RECTAL SPECIALISTS

Business review letters (July 1, 1996), **App. C69**

ALLIED HEALTH PRACTITIONERS

In credentialing process, § 13:19

ALL-PRODUCTS PROVISIONS

Health plan market power, payer monopoly power and all-products provisions, § 21:7

ALPENA PUBLIC SCHOOLS

FTC staff advisory opinion to (June 16, 2006), **App. D114**

**AMBULATORY SURGERY
CENTERS (ASCS)**

Physician-owned facilities, § 18:2 et seq.

**AMERICAN ANTITRUST
INSTITUTE**

Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care, text of remarks of Martin Gaynor, Director, Bureau of Economics, FTC, before the 2014 Annual Conference, **App. E234**

**AMERICAN ASSOCIATION OF
OPHTHALMOLOGY**

Business review letter, **App. C8**

AMERICAN BAR ASSOCIATION

- Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed Answers, text of remarks of Joshua D. Wright, Commissioner, FTC, before the ABA Master Course VII (Oct. 10, 2014), **App. E235**
- Enforcement Strategies in the Health Care Industry, prepared remarks of J. Thomas Rosch before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**
- Observations on and From the Antitrust Division's buyer-side cases: How can 'lower' prices violate the antitrust laws, remarks of Mark Botti at Antitrust Law Spring Meeting (Apr. 19, 2007), **App. E147**
- Origin of the Species: The 100 Year Evolution of the Clayton Act, text of remarks of William J. Baer, Assistant Attorney General, Antitrust Division, before the ABA Clayton Act 100th Anniversary Symposium (Dec. 4, 2014), **App. E237**
- Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission, Joshua D. Wright

**AMERICAN BAR ASSOCIATION
—Cont'd**

before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

What's Past is Prologue: FTC's Competition and Consumer Protection Priorities, text of remarks by Julie Bill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**

**AMERICAN DENTAL
ASSOCIATION**

Advisory opinions
August 26, 1985, **App. D15**
February 15, 1990, **App. D28**

**AMERICAN HEART
ASSOCIATION**

Business review letter, **App. C27**

**AMERICAN HEART
ASSOCIATION
PHARMACEUTICAL
ROUNDTABLE**

Business review letters (Mar. 20, 1998), **App. C85**

**AMERICAN HOSPITAL
ASSOCIATION**

Business review letter, **App. C5**
Clinical Integration: The Changing Climate and What It Means for Care Coordination, remarks of Pamela Jones Harbour, Commissioner, FTC at annual membership meeting (Apr. 27, 2009), **App. E170**

**AMERICAN INTRA-OCULAR
IMPLANT SOCIETY**

Advisory opinion, **App. D17**

**AMERICAN MEDICAL
ASSOCIATION**

Advisory opinions (March 26, 1996), **App. D62**
Business review letters and advisory opinion
December 2, 1986, **App. C20**

INDEX

AMERICAN MEDICAL

ASSOCIATION—Cont'd

Business review letters and advisory opinion—Cont'd

February 14, 1994, **App. D42**

March 9, 1979, **App. C7**

AMERICAN PODIATRY ASSOCIATION

Advisory opinions

August 18, 1983, **App. D4**

March 13, 1984, **App. D7**

AMERICAN RED CROSS

Business review letter, **App. C21**

AMGEN INC. AND HORIZON THERAPEUTICS PLC, FTC FILE NO. DO9414

Consent order agreement, **App. N8**

AMICUS BRIEF

FTC, Jazz Pharmaceuticals v. Avadel
CNS Pharmaceuticals, **App.
D207**

ANCILLARY PRICE-FIXING AGREEMENTS

Provider-controlled contracting
networks, clinical integration,
§ 20:8

ANDREW N. FERGUSON & MELISSA HOLYOAK STATEMENT

Gateway Pet Memorial Services,
App. F9

ANNUAL ANTITRUST SEMINAR

“The Rhetoric of Gun Jumping,”
remarks before Association of
Corporate Counsel Annual
Antitrust Seminar of Greater
New York Chapter (Nov. 10,
2005), **App. E138**

ANNUAL REPORT

FTC and Department of Justice 44th
Hart-Scott-Rodino, **App. D209**

ANTHEM, INC.

Acquisition of WellPoint Health
Networks, Inc., Antitrust Divi-
sion statement on closing of

ANTHEM, INC.—Cont'd

investigation of (March 9,
2004), **App. E128**

“ANTICOMPETITIVE ASPECTS OF EXCLUSIVE DEALING AND RELATED PRACTICES”

(Speech), **App. E88**

ANTICOMPETITIVE CONDUCT (MONOPOLIZATION)

Generally, § 6:4

Denial of access to essential facility,
§ 6:8

Leveraging, § 6:9

Mergers, § 6:11

Monopoly pricing, § 6:5

Other predatory or unreasonably
exclusionary conduct, § 6:12

Predatory pricing, § 6:6

Refusals to deal, § 6:7

Vertical integration, § 6:10

ANTICOMPETITIVE EFFECT ELEMENT (SHERMAN ACT SECTION 1 VIOLATIONS)

Hybrid analyses, § 3:13

Per se rule, § 3:12

Rule of reason, § 3:11

Unreasonably, generally, § 3:10

ANTICOMPETITIVE PURPOSE OR INTENT ELEMENT

Civil antitrust cases, § 3:8

Criminal antitrust cases, § 3:9

Intent in criminal antitrust cases,
§ 3:9

Of Sherman Act Section 1 violations,
§ 3:7

Purpose and intent in civil antitrust
cases, § 3:8

ANTI-KICKBACK STATUTE

“Statement to Negotiated Rulemak-
ing Committee on Shared Risk
Exception to Anti-Kickback
Statute” (speech), **App. E77**

ANTITRUST, JUDICIARY SUBCOMMITTEE

Competition Policy and Consumer
Rights Oversight of the Enforce-

ANTITRUST, JUDICIARY

SUBCOMMITTEE—Cont’d

ment of the Antitrust Laws,
United States Senate Committee
on the Judiciary Subcommittee
on Antitrust, **App. E287**

**“ANTITRUST ANALYSIS OF
HOSPITAL NETWORKS AND
SHARED SERVICES
ARRANGEMENTS”**

(Speech), **App. E65**

**“ANTITRUST AND HEALTH
CARE PROVIDERS:
POLICIES TO PROMOTE
COMPETITION AND
PROTECT PATIENTS”**

Rebecca Kelly Slaughter, prepared
remarks, **App. E267**

ANTITRUST CIVIL PROCESS ACT

Generally, **App. A9**

ANTITRUST DEFENSES

See also Defenses (this index)
To defense actions in nonantitrust
cases, § **11:12**

ANTITRUST DIVISION

Price Fixing, Bid Rigging, and Mar-
ket Allocation Schemes
what they are and what to look for,
antitrust primer
Department of Justice, **App.N39**

**ANTITRUST DIVISION,
DEPARTMENT OF JUSTICE**

Justice Department (United States
Department of Justice; Antitrust
Division) (this index)

ANTITRUST GUIDELINES

Federal trade commission (ftc)
DOJ and FTC Antitrust Guidelines
for Business Activities Affect-
ing Workers
(January 2025), **App. N26**

**ANTITRUST/HEALTH CARE
GUIDELINES**

Generally, **App. F**

**ANTITRUST/HEALTH CARE
GUIDELINES—Cont’d**

ABA/AHLA Antitrust in Healthcare
Conference, Christine A. Varney
prepared remarks, **App. E181**

“An Ounce of Antitrust Prevention is
Worth a Pound of Consumer
Welfare: The Importance of
Competition Advocacy and
Premerger Notification,” before
Eleventh Annual Competition
Day, Santiago, Chile (Nov. 5,
2013), **App. E225**

“Antitrust and Health Care Provid-
ers: Policies to Promote Compe-
tition and Protect Patients,”
Rebecca Kelly Slaughter, pre-
pared remarks, **App. E267**

Antitrust Division Evaluation of
Corporate Compliance Programs
in Criminal Antitrust Investiga-
tions (November 2024), **App.
N20**

Antitrust in Healthcare Conference:
A Perscription for Competition,
Benard A. Nigro, Jr., prepared
remarks, **App. E263**

FTC topic and yearly indices of advi-
sory opinions, commission and
staff (December 2025), **App. L3**

“Patent Settlements, Patent Reform,
and Mergers: Recent Develop-
ments in Pharmaceutical
Antitrust,” **App. E190**

Telehealth services, advocacy letter
to Antitrust Division (Nov. 29,
2016), **App. C105**

“The FTC’s Role in Shaping
Antitrust Doctrine: Recent Suc-
cesses and Future Targets,”
Joshua D. Wright before the
2013 Georgetown Global
Antitrust Symposium Dinner,
Washington, D.C. (Sept. 24,
2013), **App. E223**

US GAO Report, stakeholders
perspectives, adequacy of guid-
ance, **App. B15**

**“ANTITRUST IN HEALTHCARE:
A KEYNOTE ADDRESS”**

(Speech), **App. E124**

INDEX

“ANTITRUST IN HEALTHCARE: A KEYNOTE ADDRESS”

—Cont’d

FTC chairwoman, Health Law
Conference (May 12, 2016),
App. E252

ANTITRUST IN HEALTHCARE CONFERENCE: A PERScription FOR COMPETITION

Remarks, text of, prepared for, **App.
E263**

ANTITRUST IN HEALTH CARE SEMINAR

“Clinical Integration in Antitrust:
Prospects for the Future,”
remarks before AHLA and ABA
Antitrust and Health Law Sec-
tion 2007 Antitrust in Health
Care Seminar, prepared remarks
of J. Thomas Rosch, Commis-
sioner, FTC (Sept. 17, 2007),
App. E154

“ANTITRUST ISSUES RAISED BY RURAL HEALTH CARE NETWORKS”

(Speech), **App. E80**

ANTITRUST LAW 2007 FALL FORUM

Prepared slides of Jeffrey Schmidt,
Director, Bureau of Competi-
tion, before ABA Section
concerning “Critical Loss Anal-
ysis: A Merger Lawyer’s View”
(Nov. 16, 2007), **App. E157**

ANTITRUST LAWS

Generally, § 1:1

See also more specific entries
throughout this index

Conclusion, § 1:9

Federal government guidelines, § 1:8

Goals of, § 1:4

Government enforcement statements,
§ 1:7

Health care and, § 1:5

History and overview of, § 1:3

ANTITRUST LAWS—Cont’d

History of enforcement of, in health
care sector, § 1:6

Legislative changes, § 1:7

Managed care, effect of, § 1:7

Provider-controlled contracting
networks, price-fixing agree-
ments, § 20:11

Purpose and definition of, § 1:2

Relevant federal, in mergers, § 15:3

Resources, § 1:10

ANTITRUST SAFETY ZONE

Provider-controlled contracting
networks, § 20:5, § 20:6

ANY-WILLING-PROVIDER LAWS (FTC LETTERS)

To the Attorney General of North
Dakota regarding, **App. D36**

To the California Senate regarding,
App. D33

To the New Hampshire Senate
regarding, **App. D32**

APRNS

Senator Brad Hutto FTC Clarke
Edwards Letter, **App. D214**

ASSOCIATES IN NEUROLOGY

Advisory opinions (Aug. 13, 1998),
App. D83

ASSOCIATION OF CORPORATE COUNSEL

“The Rhetoric of Gun Jumping,”
remarks before Association
(Nov. 10, 2005), **App. E138**

ASSOCIATION OF QUALITY HEALTH CARE

Advisory opinion, **App. D22**

ATTEMPTED MONOPOLIZATION

Diversification and, under Section 2,
Sherman Act

generally, § 17:8

essential facilities doctrine and,
§ 17:10

leveraging and, § 17:11

predatory refusals to deal, § 17:9

**ATTEMPTED MONOPOLIZATION
—Cont’d**

Under Section 2, Sherman Act
generally, § **6:13**
dangerous probability of success,
§ **6:15**
specific intent and predatory
conduct, § **6:14**

AUTHORITY

FTC enforcement, § **10:7**

BAER, WILLIAM J.

“Origin of the Species: The 100 Year
Evolution of the Clayton Act,”
text of remarks of William J.
Baer, Assistant Attorney Gen-
eral, Antitrust Division, before
the ABA Clayton Act 100th
Anniversary Symposium (Dec.
4, 2014), **App. E237**

BARRIERS TO GENERIC ENTRY

Special Committee on Aging, U.S.
Senate, Prepared Statement of
FTC Before (July 20, 2006),
App. E142

**BATES WHITE ANNUAL
ANTITRUST CONFERENCE**

“Litigating Merger Challenges: Les-
sons Learned,” prepared
remarks by J. Thomas Rosch at
Fifth Annual Antitrust Confer-
ence (June 2, 2008), **App. E165**

**BAXTER HEALTHCARE
CORPORATION**

Business review letter, **App. C26**

**BAY AREA BUSINESS GROUP ON
HEALTH**

Business review letter, **App. C37**

**BAY AREA PREFERRED
PHYSICIANS**

Advisory opinion, **App. D104**

BEDOYA, ALVARO M.

Adoption of the Statement of
Enforcement Policy, Unfair
Methods of Competition Under
Section 5 of the FTC Act, **App.
E288**

BELJING, CHINA

Joshua D. Wright, “Recent Antitrust
Enforcement Initiatives at the
U.S. Federal Trade Commis-
sion,” before the ABA Section
of International Law Confer-
ence, Beijing, China (Sept. 16,
2013), **App. E222**

BIDDING

Agreements not to engage in compet-
itive, ethical restraints on, § **24:4**

BID-RIGGING AGREEMENTS

Horizontal, under Section 1, Sherman
Act, § **4:5**

**“BIGGER THAN BIG TECH? THE
NEED TO REFORM OUR
HEALTH CARE MARKETS
USING CHOICE AND
COMPETITION” CHRISTINE
S. WILSON, (SEPTEMBER 9,
2019)**

Federal trade commission (ftc), **App.
E269**

BIOSIMILARS

FDA/FTC workshop
competitive marketplace for
biosimilars, **App. D208**
opening remarks of Chairman
Joseph Simons, **App. E271**

**BIRMINGHAM COOPERATIVE
CLINICAL BENCHMARKING
DEMONSTRATION PROJECT**

Business review letter, **App. C42**

BISHOP, MICHAEL D.

Antitrust Division letter to Michigan
Senate Majority Leader Bishop
concerning proposed standards
of Michigan Certificate of Need
Commission (June 6, 2008),
App. C100

BJC HEALTH SYSTEM

Advisory opinions (Nov. 9, 1999),
App. D87

BLUMENTHAL, WILLIAM

“The Rhetoric of Gun Jumping,”
remarks before Association of

INDEX

BLUMENTHAL, WILLIAM

—Cont'd

Corporate Counsel Annual
Antitrust Seminar of Greater
New York Chapter (Nov. 10,
2005), **App. E138**

BONE & JOINT CENTER OF MOBILE, PA

Business review letters (Apr. 16,
1997), **App. C79**

BOYCOTTS

Physician-owned facilities, § 18:3
Practitioner credentialing, analysis
under Section 1 of Sherman Act,
§ 13:10 to 13:17

BRIBERY

Commercial, as vertical agreement
under Section 1, Sherman Act,
§ 5:9

BRILL, JULIE

“A Common Goal: The U.S. Federal
Trade Commission’s Healthcare
Enforcement Program and its
Implications for ACOs,” text of
remarks by Julie Brill, Commis-
sioner, FTC, before the Sixth
Annual Accountable Care Orga-
nization Summit Preconference
(June 17, 2015), **App. E244**

“Bending the Cost Curve: The View
from the Federal Trade Commis-
sion,” speech by Julie Brill,
FTC Comm., **App. E206**

“Competition in Health Care
Markets,” text of remarks by
Julie Brill, Commissioner, FTC,
at 2014 Hal White Antitrust
Conference (June 9, 2014), **App.
E231**

North Carolina Bar Assoc., prepared
remarks before, **App. E198**

“What’s Past is Prologue: FTC’s
Competition and Consumer
Protection Priorities,” text of
remarks by Julie Brill, Commis-
sioner, FTC, before the ABA
Fall Forum (Nov. 6, 2014), **App.
E236**

BUREAU OF COMPETITION

Advisory opinion, guidance on
requesting and obtaining, **App.
D201**

“Antitrust Enforcement in Health
Care: Proscription, Not Prescrip-
tion,” remarks by Deborah L.
Feinstein, Director, Bureau of
Competition, FTC before the
Fifth National Accountable Care
Organization Summit (June 19,
2014), **App. E232**

FTC Staff Advisory Opinion to Mesa
County Physician Independent
Practice Association (Nov. 6,
1997), **App. D78A**

Prepared slides of Jeffrey Schmidt,
Director, before ABA Section of
Antitrust Law 2007 Fall Forum
“Critical Loss Analysis: A
Merger Lawyer’s View” (Nov.
16, 2007), **App. E157**

Statement of the Federal Trade Com-
mission’s Bureau of Competi-
tion on Guidelines for Merger
Investigations (Dec. 11, 2002),
App. B3F

“The Forward-Looking Nature of
Merger Analysis,” remarks by
Deborah L. Feinstein, Director,
Bureau of Competition, FTC
(Feb. 6, 2014), **App. E230**

BURNS, TIMOTHY G.

FTC letter to Hon. Timothy G. Burns,
Louisiana House of Representa-
tives, concerning in-school den-
tistry regulation (May 1, 2009),
App. D128

BUSINESS

See also Companies; Firms (this
index)

As element of damage action, § 11:4

Partial integration of functions. Joint
Ventures (this index)

BUSINESS HEALTH COMPANIES, INC.

Advisory opinions
(Oct. 19, 1996), **App. D66**
(Oct. 22, 1996), **App. D72**

BUSINESS JUSTIFICATION

Legitimate, exclusive contracts and,
§ 14:9

BUSINESS OF INSURANCE

As antitrust exemption, § 9:10

BUSINESS REVIEW LETTERS

Generally, **App. C et seq., App. C7, App. C20, App. E106**

AdviNet, Inc., **App. C53**

Allergy & Asthma Consultants, Inc.
(April 24, 1996), **App. C66**

Allied Colon and Rectal Specialists
(July 1, 1996), **App. C69**

American Association of
Ophthalmology, **App. C8**

American Heart Association, **App. C27**

American Heart Association
Pharmaceutical Roundtable
(Mar. 20, 1998), **App. C85**

American Hospital Association, **App. C5**

American Medical Association, **App. C7**

American Red Cross, **App. C21**

Baxalta, Emergent BioSolutions,
Grifols Therapeutics, and CSL
Plasma, **App. C107**

Baxter Healthcare Corporation, **App. C26**

Bay Area Business Group on Health,
App. C37

Bone & Joint Center of Mobile, PA
(Apr. 16, 1997), **App. C79**

California Chiropractic Association,
App. C36

California Pharmaceutical Association,
App. C2

Case Western University School of
Medicine, **App. C30**

Central Virginia Health Systems
Agency, **App. C9**

CEO Roundtable on cancer (Sept. 28,
2008), **App. C101**

Certificate-of-need regulation (Dec.
8, 2006), **App. C99**

Chicagoland Radiological Network,
App. C49

BUSINESS REVIEW LETTERS

—Cont'd

Children's Healthcare, P.A. (March 1,
1996), **App. C62**

Cincinnati Regional Orthopedic and
Sports Medicine Associates, Inc.
(Oct. 4, 1996), **App. C74**

CVT Surgical Center and Vascular
Surgery Associates of Baton
Rouge (Apr. 16, 1997), **App. C80**

Danbury Surgical Associates, **App. C24**

December 2, 1986, **App. C20**

Demonstration Project, **App. C42**

Department of Justice. See entries
throughout this topic

Dermatologists, review letter to Dr.
Oswald L. Mikell regarding
proposed network of, **App. C56**

Dermnet, Inc. (Dec. 5, 1995), **App. C59**

Des Moines Collaborative Provider
Organization, Inc., **App. C44**

Diana West (May 25, 2004), **App. C98**

Eli Lilly, AbCellera Biologics,
Amgen, AstraZeneca,
Genentech, and GSK, **App. C108**

El Paso Surgical Group (July 24,
1996), **App. C71**

February 5, 2002, **App. E106**

First Priority Health (Nov. 3, 1997),
App. C84

Gainsharing program, Greater New
York Hospital Assoc., **App. C104**

Gales Rexall Drug, **App. C1**

Gastroenterology Associates, Ltd
(July 7, 1997), **App. C82**

Georgia Preferred Podiatric Medical
Network (Nov. 3, 1995), **App. C58**

GI Associates, P.C. (July 7, 1997),
App. C82

Hanger Orthopedic Group, Inc. (Sept
15, 1995), **App. C55**

Health and Personal Care Confer-
ence, Inc., **App. C34**

INDEX

BUSINESS REVIEW LETTERS

—Cont'd

Health Care Management Associates,
App. C14
Heritage Alliance and Lackawanna
Physicians Organization (Sept.
15, 1998), **App. C86**
Hillhaven Corp., **App. C51**
Home Care Alliance, Inc. (Oct. 4,
1996), **App. C73**
Hospice Network of New Jersey, Inc.
(April 24, 1996), **App. C67**
Hospital Corporation of America,
App. C15
Hotel Employees and Restaurant
Employees International Union
Welfare Fund, **App. C41**
Houston Health Care Coalition, **App.**
C39
Hyatt Ott & Blount, P.C., **App. C28**
Independent Drug Wholesalers
Group, **App. C23**
International Chiropractors Associa-
tion, **App. C3**
International Chiropractors Associa-
tion of California, **App. C46**
Itasca Clinic and Grand Rapids Medi-
cal Associates (March 19, 1996),
App. C65
Lexecon Health Service, **App. C17**
Linen Systems for Healthcare, LLC
(Aug. 8, 2006), **App. C97**
March 9, 1979, **App. C7**
Marin General Hospital (Feb. 11,
1997), **App. C77**
Maryland Health Care Coalition,
App. C11
Memorial Health, Inc. (Sept. 4,
2009), **App. C102**
Michigan Hospital Group, Inc. (April
3, 2002), **App. C93**
Mid-South Health Plan, **App. C52**
Midwest Behavioral Health LLC
(Feb. 4, 2000), **App. C90**
Morros & Associates, **App. C6**
National Cardiovascular Network,
Inc., **App. C32**
New Jersey Hospital Association,
App. C38

BUSINESS REVIEW LETTERS

—Cont'd

North Mississippi Health Services,
App. C22
Northwestern National Life Insurance
Company, **App. C50**
NSM Purchasing Association (Jan.
13, 1999), **App. C88**
Ohio Hospital Purchasing
Consortium, **App. C13**
Oklahoma Physicians Network-IPA,
Inc. (Jan. 17, 1996), **App. C61**
Olympus America, Ind. (Aug. 29,
2001), **App. C92**
Optometric care, **App. D109**
Orange Los Angeles Medical Group,
Inc. (March 8, 1996), **App. C64**
Orthopedic Associates of Mobile, PA
(Apr. 16, 1997), **App. C79**
Pacific Business Group on Health
(Apr. 26, 2010), **App. C103**
Pennsylvania Insurance Commis-
sioner, **App. C31**
Pennsylvania Orthotics & Prosthetics
Enterprise, **App. C54**
Pharmaceutical benefit managers
regulation, letter to Virginia
House of Delegates (Oct. 2,
2006), **App. D116**
Pharmaceutical Care Network, **App.**
C18
Pharmaceutical Manufacturers
Association, **App. C33**
Pharmacy benefit managers
("PBMs") and "covered enti-
ties," House Bill 1332 ("HB
1332" or the "Bill") that would
regulate the contractual relation-
ships between, **App. D108**
Physician Care, Inc., **App. C47**
Plastic Surgery Associates of Con-
necticut, LLC (June 28, 1996),
App. C68
PPE collaboration, **App. C106**
Preferred Laboratory Access Network
(Dec. 7, 1995), **App. C60**
Preferred Physicians Medical Group
(July 23, 1999), **App. C89**
Preferred Podiatric Network Inc.,
App. C45

BUSINESS REVIEW LETTERS

—Cont'd

- Primary and Specialist Medical Center, LLC (July 2, 1996), **App. C70**
- PROklahoma Care, Inc. (Jan. 17, 1996), **App. C61**
- Pulmonary Associates, Ltd., and Albuquerque Pulmonary Consultants, P.A., **App. C48**
- Relating to Wisconsin Rate Review Program, **App. C4**
- Rio Grande Eye Associates, P.A., **App. C91**
- Ross Hospital (Feb. 11, 1997), **App. C77**
- RWHC Network, Inc. (Nov. 12, 1996), **App. C76**
- Santa Fe, New Mexico Managed Care Organization, Inc. (Feb. 12, 1997), **App. C78** (Sept. 16, 1998), **App. C87**
- Seeskin, Paas, Blackburn & Co., **App. C43**
- Service For You, **App. C19**
- Sierra CommCare, Inc. (Aug. 15, 1996), **App. C72**
- South Carolina State Health Planning Committee, concerning certificate-of-need regulation (Dec. 8, 2006), **App. C99**
- Southern Health Corporation (March 5, 1996), **App. C63**
- Southwestern Michigan Health Systems Agency, **App. C12**
- Southwest Oncology Group (Nov. 2, 1995), **App. C57**
- Southwest Orthopedic Specialists (June 10, 1997), **App. C81**
- St. Anthony Medical Center, **App. C35**
- Stark County Health Care Coalition, **App. C16**
- St. Joseph's/Candler Health System (Sept. 4, 2009), **App. C102**
- St. Louis Area Business Health Coalition, **App. C25**
- Terence L. Smith, M.D. (Oct. 17, 1996), **App. C75**

BUSINESS REVIEW LETTERS

—Cont'd

- To Senator Howard Metzenbaum, **App. C40**
- Transplant Associates, **App. C29**
- Valley Gastroenterologists (July 7, 1997), **App. C82**
- Vermont Physicians Clinic (July 30, 1997), **App. C83**
- Virginia House of Delegates concerning regulation of pharmaceutical benefit managers (Oct. 2, 1997), **App. D116**
- Washington State Medical Association, **App. C94**
- Westlake Health Campus Association, **App. C10**

BUSINESS REVIEW PROCEDURE

- Of Antitrust Division enforcement, § 10:6, **App. B4**

“BUYER POWER CONCERNS AND THE AETNA/PRUDENTIAL MERGER”

- (Speech), **App. E91**

CALIFORNIA CHIROPRACTIC ASSOCIATION

- Business review letter, **App. C36**

CALIFORNIA MANAGED IMAGING MEDICAL GROUP, INC.

- Advisory opinion, **App. D40**

CALIFORNIA PHARMACEUTICAL ASSOCIATION

- Business review letter, **App. C2**

CANADA

- Dental licenses, FTC staff comment on New York's proposal to allow licensure by endorsement of Canadian, **App. D199**

CANCER

- Business Review Letter to CEO Roundtable on clinical trials for cancer treatments (Sept. 28, 2008), **App. C101**

INDEX

CAPACITY

To conspire, practitioner credentialing and, Section 1 of Sherman Act, § **13:11**

CAREMARK RX/ADVANCEPCS MERGER

FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**

CASE WESTERN UNIVERSITY SCHOOL OF MEDICINE

Business review letter, **App. C30**

CAUSATION

As element of damage action, § **11:5**

CENTERS FOR MEDICARE AND MEDICAID SERVICES

Medicare prescription drug benefit programs, FTC Staff Advocacy Letter to CMMS concerning any-willing-provider changes (Mar. 7, 2014), **App. D164**

CENTRAL TEXAS MEDICAL GROUP

Advisory opinions (Sept. 28, 1995), **App. D58**

CENTRAL VIRGINIA HEALTH SYSTEMS AGENCY

Business review letter, **App. C9**

CEO ROUNDTABLE

Business Review Letter to CEO Roundtable on cancer (Sept. 28, 2008), **App. C101**

CERTIFICATE-OF-NEED (CON)

Agency opposition, § **22:3**

Alaska Senate Committee on Labor and Commerce, Certificate-of-Need Laws and SB 62, statement of FTC (Feb. 6, 2018), **App. E256**

Antitrust ramifications of certificate-of-need proceedings, § **22:4**

“Competition in healthcare and certificate of need” prepared testimony of U.S. Department of Justice Antitrust Division to

CERTIFICATE-OF-NEED (CON)

—Cont’d

Georgia General Assembly (Feb. 23, 2007), **App. E145**

Federal Trade Commission prepared statement before Alaska House of Representatives (Feb. 15, 2008), **App. E159**

Federal Trade Commission prepared statement before Florida State Senate (Apr. 2, 2008), **App. E163**

Federal Trade Commission Staff advocacy letter concerning bill to modify North Carolina law (July 10, 2015), **App. D174**

FTC and Antitrust Division joint statement to Alaska House of Representatives, (Apr. 7, 2017), **App. D194**

FTC statement to Alaska Senate on CON laws and Bill 62 (Feb. 6, 2018), **App. D197**

Letter from Joseph Miller, Assistant Chief, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, concerning proposed standards (June 6, 2008), **App. C100**

Letter from U.S. Department of Justice Antitrust Division to South Carolina State Health Planning Committee concerning regulation (Dec. 8, 2006), **App. C99**

Physician-owned facilities, hospital’s opposition, § **18:3**

Pros and cons, § **22:3**

South Carolina, joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D179**

Virginia, joint statement of FTC and Antitrust Division to Virginia Certificate of Need Work Group (Oct. 26, 2015), **App. D177**

CERTIFICATE OF PUBLIC ADVANTAGE

“A Health Care Check on COPAs; Assessing the Impact of Certifi-

**CERTIFICATE OF PUBLIC
ADVANTAGE—Cont'd**

cates of Public Advantage in
Health Care Markets” Joseph J.
Simons, remarks, (June 18,
2019), **App. E268**

FTC Staff advocacy letter to Malaka
Watson, Tennessee Department
of Health, concerning coopera-
tive agreements and certificates
of public advantage (Sept. 24,
2015), **App. D176**

**CERTIFICATES OF PUBLIC
ADVANTAGE**

FTC policy, **App. D205**

CHILDREN’S HEALTHCARE, P.A.

Business review letters (March 1,
1996), **App. C62**

CHINA

“Recent Antitrust Enforcement
Initiatives at the U.S. Federal
Trade Commission,” Joshua D.
Wright before the ABA Section
of International Law Confer-
ence, Beijing, China (Sept. 16,
2013), **App. E222**

**CINCINNATI REGIONAL
ORTHOPEDIC AND SPORTS
MEDICINE ASSOCIATES,
INC.**

Business review letters (Oct. 4,
1996), **App. C74**

**CIVIL ANTITRUST
INVESTIGATION BASICS**

(Speech), **App. E66**

CIVIL ENFORCEMENT

See also Enforcement (this index)
By Antitrust Division, § **10:4**

CLAYTON ACT

100th anniversary, “Origin of the
Species: The 100 Year Evolution
of the Clayton Act,” text of
remarks of William J. Baer,
Assistant Attorney General,
Antitrust Division, before the
ABA Clayton Act 100th Anni-

CLAYTON ACT—Cont’d

versary Symposium (Dec. 4,
2014), **App. E237**

Section 7

generally, § **8:1**

Antitrust Division and Federal
Trade Commission, § **8:18**

conclusion, § **8:20**

conglomerate mergers, § **8:15**

diversification and, § **17:7**

joint ventures, § **8:16**

mergers and, § **15:3**

preliminary issues, § **8:2**

premerger notification require-
ments, § **8:17**

relevant markets, § **8:4**

2010 merger guidelines and merger
analysis, § **8:3**

vertical mergers, § **8:14**

Section 8, § 7:12

Section 7A, Hart Scott-Rodino
premerger notification filings
revised jurisdictional thresholds,
App. B26

Section 7A, premerger notification
form and instructions under
amended, **App. B3**

Section 7: horizontal mergers

generally, § **8:5**

collusion, market characteristics
and ease of, § **8:10**

concentration, § **8:6**

defenses, § **8:13**

efficiencies from merger, § **8:12**

financial viability, § **8:11**

guidelines, Department of Justice
and Federal Trade Commis-
sion, § **15:9, App. B6**

other factors, § **8:7**

Section 2. Robinson-Patman Act (this
index)

Text of, excerpts, **App. A2**

CLEARANCE PROCEDURES

Memorandum of Agreement between
FTC and Antitrust Division of
the U.S. Dept. of Justice
concerning clearance procedures
for investigations, **App. B7**

INDEX

CLINICAL INTEGRATION

“Clinical Integration: The Changing Climate and What It Means for Care Coordination” (Apr. 27, 2009), remarks of Pamela Jones Harbour, Commissioner, FTC, **App. E170**

Provider-controlled contracting networks, ancillary price-fixing agreements and clinical integration, § **20:8**

TriState Health Partners, FTC letter not to recommend challenge of proposed “clinical integration” of members’ provision of health care services (Apr. 13, 2009), **App. D127**

CLINICAL TRIAL AGREEMENT

Business Review Letter to CEO Roundtable on cancer (Sept. 28, 2008), **App. C101**

COLLABORATION GUIDELINES

Generally, **App. G, App. G1**

Antitrust guidelines for collaborations among competitors, § **3:14**

Medical school collaboration agreements, FTC Staff Advocacy letter to Alabama State Senate concerning antitrust exemption (May. 2, 2016), **App. D186**

Overview of, § **16:6**

State-action protection to certain collaborative activity, FTC Staff Advocacy letter to West Virginia House of Delegates concerning (Mar. 9, 2016), **App. D183**

COLLECTIVE BARGAINING

FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**

Legislative exemption, letter from FTC to Insurance Committee, Ohio House of Representatives, **App. D95**

COLLECTIVE NEGOTIATION OF FEES

FTC Staff letter to Puerto Rico Treasury and Financial Affairs Com-

COLLECTIVE NEGOTIATION OF FEES—Cont’d

mittee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D121**

COLUMBINE FAMILY HEALTH CENTER

Advisory opinions (Nov. 89, 1995), **App. D59**

COLUMBUS HOSPITAL

Advisory opinions (June 28, 1996), **App. D65**

“COMBINATION AND COLLABORATION IN HEALTH CARE MARKETS: ANTITRUST AS A CONSTRAINT IN A TIME OF CHANGE”

Speech, **App. E41**

COMMERCIAL BRIBERY

As vertical agreement under Section 1, Sherman Act, § **5:9**

COMMUNITY AND PAYER MORAL SUASION

Physician-owned facilities, § **18:3**

COMMUNITY CAREPARTNERS

Federal Trade Commission (FTC), staff advisory opinion to Community CarePartners concerning the Non-Profit Institutions Act, **App. D132**

COMMUNITY HOSPITAL, INC.

Advisory opinions (Dec. 22, 1997), **App. D79**

COMMUNITY PHARMACY FAIRNESS ACT

Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee concerning HR 971, “Community Pharmacy Fairness Act of 2007” (Oct. 18, 2007)—David Wales, Bureau of Competition, **App. E156**

COMPANIES

See also Business (this index)

COMPETITION

See more specific entries throughout this index

COMPETITIVE BIDDING

Agreements not to engage in, ethical restraints on, § 24:4

COMPETITIVE EFFECTS

Under Section 2(a), Robinson-Patman Act, § 7:5

**COMPETITIVELY SENSITIVE
HEALTH CARE
INFORMATION**

Federal Trade Commission advocacy letter to Minnesota House of Representatives regarding a bill to permit disclosure (June 29, 2015), **App. D173**

COMPETITIVE MARKETPLACE

Summary report, FDA/FTC workshop for biosimilars, **App. D208**

COMPETITOR IDENTIFICATION

Mergers and, § 15:12

CONCENTRATION

Mergers and
as factor in horizontal merger under Section 7 of Clayton Act, § 8:6

CONFLICTS OF INTEREST

Physician-owned facilities, § 18:2, § 18:3

CONGLOMERATE MERGERS

Under Section 7 of Clayton Act, § 8:15

**CONNECTICUT BAR
ASSOCIATION**

“Health Care Technology: Promoting Competition and Protecting Innovation,” Maureen K. Ohlhausen, Commissioner of FTC, before Connecticut Bar Association Antitrust amp:

CONNECTICUT BAR

ASSOCIATION—Cont’d

Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E228**

**CONNECTICUT HOSPITAL
ASSOCIATION**

Advisory opinions (Dec. 20, 2001), **App. D91**

CONSENT ORDER

Amgen Inc. and Horizon Therapeutics plc, FTC File No. DO9414, **App. N8**

In the Matter of (Insulin) Caremark Rx, Zinc Health Services, et al., agreement containing, express scripts defendants, **App. F14**

In the Matter of Centerbridge Seaport Acquisition Fund, L.P., agreement containing, **App. F13**

CONSPIRACY

See also Agreements (this index)

Capacity to conspire, practitioner credentialing and, under Section 1, Sherman Act, § 13:11

In fact, practitioner credentialing and, under Section 1 of Sherman Act, § 13:12

To monopolize, § 6:16

CONSUMER

Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, **App. E287**

“Interface of Competition and Consumer Protection” (October 31, 2002), **App. E113**

CONTRACTS

Exclusive. Exclusive Contracts (this index)

Networks. Provider-Controlled Contracting Networks (this index)

COOPERATIVE AGREEMENTS

FTC Staff advisory letter to Susan Puglisi, Virginia Department of Health, concerning cooperative

INDEX

COOPERATIVE AGREEMENTS

—Cont'd

agreements (Sept. 17, 2015),
App. D175

FTC Staff advocacy letter to Malaka
Watson, Tennessee Department
of Health, concerning coopera-
tive agreements and certificates
of public advantage (Sept. 24,
2015), **App. D176**

CORONAVIRUS

DOJ and FTC joint antitrust state-
ment regarding COVID-19
(March 2020), **App. K1**

“COST-SHIFTING”

Physician-owned facilities, § **18:2**

COVENANTS

Horizontal, not to compete, under
Section 1 of Sherman Act, § **4:6**

COVID-19

DOJ and FTC joint antitrust state-
ment regarding COVID-19
(March 2020), **App. K1**

CREDENTIALING

Practitioner Credentialing (this index)

CREDIT SUISSE 2018

WASHINGTON PERSPECTIVES CONFERENCE

Remarks at, (Jan. 10, 2018), **App.
E262**

CRIMINAL ENFORCEMENT

See also Enforcement (this index)
By Antitrust Division, § **10:3**

CROSS-MARKET

Mergers, § **15:29**

“CROSS-SUBSIDIZATION”

Physician-owned facilities, § **18:2**

“CURRENT ISSUES IN HEALTH CARE ANTITRUST ENFORCEMENT AT FTC”

(Speech), **App. E67**

CVT SURGICAL CENTER AND VASCULAR SURGERY ASSOCIATES OF BATON ROUGE

Business review letters (Apr. 16,
1997), **App. C80**

DAMAGES

Private actions, § **11:1**

DANBURY SURGICAL ASSOCIATES

Business review letter, **App. C24**

DEAL

Refusals to Deal (this index)

DEALING AGREEMENTS

Under Section 1, Sherman Act
exclusive dealing, § **5:7**
reciprocal dealing, § **5:8**

DEFENSES

Damage action
generally, § **11:9**
antitrust defenses in nonantitrust
cases, § **11:12**
in pari delicto and related defenses,
§ **11:11**
statute of limitations, § **11:10**
Mergers, failing company, § **15:20**
To horizontal mergers under Section
7 of Clayton Act, § **8:13**
Under Section 2(a), Robinson-Pat-
man Act, § **7:6**

DELAWARE

Board of Dietetics/Nutrition,
Telehealth Dietetic and Nutrition
Services), FTC staff advocacy
letter (Aug. 16, 2016, **App.
D190**
Board of Occupational Therapy
Practice, occupational therapist
telehealth supervision, FTC staff
advocacy letter (Aug. 3, 2016),
App. D189
Board of Speech/Language Patholo-
gists, Audiologists, and Hearing
Aid Dispensers, amendment to
telecommunication and
telehealth regulations, FTC

DELAWARE—Cont'd

advocacy letter (Nov. 29, 2016),
App. D191

DENIAL OF ACCESS

To essential facility, as anticompetitive conduct under Section 2 of Sherman Act, § **6:8**

DENTISTS AND ORAL SURGEONS

Canadian dental licenses, FTC staff comment on New York's proposal to allow licensure by endorsement of, **App. D199**

Dental Accreditation Commission, **App. D161, App. D163, App. D167**

Education accreditation standards
modifications to Louisiana Rules regarding the practice of portable and mobile dentistry, FTC Staff comments to Louisiana State Board of Dentistry (Dec. 9, 2009), **App. D130**

Staff advocacy letter to Sherin Tools, Commission on Dental Accreditation (Dec. 12, 2014), **App. D167**

Staff letter to Commission on Dental Accreditation (Dec. 2, 2013), **App. D161, App. D163**

In-school dentistry regulation, FTC letter to Hon. Timothy G. Burns, Louisiana House of Representatives (May 1, 2009), **App. D128**

Practices, business organizations supporting, **App. D153**

Southwest Florida Oral Surgery Associates (Dec. 2, 1996), advisory opinions, **App. D67**

Supervision of dental hygienists, Advocacy letter to Georgia State Senate (Jan. 29, 2016), **App. D180**

Therapist licensing, staff advocacy letter (Mar. 3, 2017), **App. D192**

Utah Society of Oral and Maxillofacial Surgeons, advisory opinions, **App. D14**

DENTURISTS

FTC Advocacy letter to Kentucky House of Representatives concerning regulation (Mar. 25, 2016), **App. D185**

DEPARTMENTAL CLOSINGS

Exclusive contracts and, § **14:14**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FTC Staff advocacy letter to Department of Health and Human Services concerning interoperability of health information technology (Apr. 3, 2015), **App. D168**

DEPARTMENT OF JUSTICE

Additional information, documentary material request, **App. B9**

Antitrust Division, Price Fixing, Bid Rigging, and Market Allocation Schemes

what they are and what to look for, antitrust primer, **App. N39**

Antitrust division. Justice Department (United States Department of Justice; Antitrust Division) (this index)

DOJ and FTC 2023 Merger Guidelines, **App. B20**

DOJ Complaint in matter of U.S., et al. v. Unitedhealth Group Incorporated, et al., **App. N21**

44th Hart-Scott-Rodino annual report, **App. D209**

Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E286**

Orange book, brand drug manufacturers improper listing of patents, statement, **App. B22**

Press release, FTC, DOJ and HHS work
lower health care and drug costs, **App. B21**

Strengthen enforcement against illegal mergers, **App. B19**

DERMATOLOGISTS

Business review letters to Dr. Oswald L. Mikell regarding proposed

INDEX

DERMATOLOGISTS—Cont’d
network of, **App. C56**

DERMNET, INC.

Business review letters (Dec. 5, 1995), **App. C59**

DES MOINES COLLABORATIVE PROVIDER ORGANIZATION, INC.

Business review letter, **App. C44**

“DIAGNOSING PHYSICIAN-HOSPITAL ORGANIZATIONS”

(Speech), **App. E125**

DIRTY TRICKS

Under Section 1 of Sherman Act, as horizontal agreements, § **4:9**

DISMISSAL

Summary Judgments (this index)

DISTRIBUTORSHIP TERMINATIONS

Under Section 1 of Sherman Act, as vertical agreements, § **5:4**

DIVERSIFICATION

Provider. Provider Diversification (this index)

DOJ ANTITRUST DIVISION

Economic analysis group discussion paper

Online Reviews and Hospital Choices, EAG 22-1
December 2022, **App. N5**

DUAL DISTRIBUTION

Under Section 1 of Sherman Act, as vertical agreements, § **5:5**

DUNCHEON, MICHAEL A.

Advisory opinion, **App. D20**

DUNLAP MEMORIAL HOSPITAL

FTC staff advisory opinion to (Jan. 6, 2004), **App. D105**

EASTERN OHIO PHYSICIANS ORGANIZATION, INC.

Advisory opinions (Sept. 28, 1995), **App. D57**

ECONOMIC CREDENTIALING

Physician-owned facilities, § **18:3**

ECONOMIC EFFECTS

Of mergers, § **15:2**

ECONOMIC INTEREST

In sale of tied product, exclusive contracts and, § **14:8**

Physician-Owned Facilities (this index)

ECONOMIC TOOLS

“FTC v. Sysco: Old School Antitrust With Modern Economic Tools”
text of remarks of Deborah L. Feinstein before GCR Live
(Sept. 18, 2015), **App. E246**

EFFICIENCIES

“Efficiencies and antitrust: an Ongoing Evolution” (November 8, 2002), **App. E114**

“Efficiency Justifications for Hospital Mergers” (speech), **App. E45**

EL PASO SURGICAL GROUP

Business review letters (July 24, 1996), **App. C71**

EMMER, TOM

FTC letter to Hon. Tom Emmer, Minnesota House of Representatives, concerning rural health care cooperatives joint negotiations (Mar 18, 2009), **App. D125**

ENFORCEMENT (ANTITRUST DIVISION AND FTC)

Generally, § **10:1**

Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**

Antitrust Division

generally, § **10:2**

business review procedure

generally, § **10:6**

see also Business Review Letters (this index)

**ENFORCEMENT (ANTITRUST
DIVISION AND FTC)—Cont'd**

Antitrust Division—Cont'd

civil enforcement, § 10:4

criminal enforcement, § 10:3

organization, § 10:2

relief in civil cases, § 10:5

Edith Ramirez, “Oversight of Enforcement of Antitrust Laws,” before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E226**

Federal Trade Commission

generally, § 10:7

advisory opinions

generally, § 10:9, **App. B5**

see also Advisory Opinions (this index)

Government enforcement statements, § 1:7

History of, in health care sector, § 1:6

Joshua D. Wright, “Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

J. Thomas Rosch, “Enforcement Strategies in the Health Care Industry,” prepared remarks before the ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**

Maureen K. Ohlhausen, “When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer’s Perspective,” text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E245**

“Oversight of the Enforcement of Antitrust Law,” FTC prepared statement before U.S. Senate Committee on the Judiciary

**ENFORCEMENT (ANTITRUST
DIVISION AND FTC)—Cont'd**

(Mar 9, 2016), **App. E251**

“Oversight of the Enforcement of Antitrust Laws,” Edith Ramirez before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E226**

Oversight of the Enforcement of the Antitrust Laws FTC prepared statement before US House of Representatives (May 15, 2015), **App. E242**

Statements of enforcement policy and analytical principles relating to health care and antitrust, withdrawn, **App. F1**

Terrell McSweeney, “Reflections on an Active Year in Merger Enforcement,” keynote remarks at Antitrust Law Leaders Forum (Feb. 5, 2016), **App. E250**

EQUIPMENT

Joint ventures among competitors to provide new, § 16:9

**EQUITABLE LIFE ASSURANCE
SOCIETY OF THE UNITED
STATES**

Advisory opinion, **App. D21**

EQUITABLE RELIEF

In Federal Trade Commission, plaintiff, v. Surescripts, LLC stipulated order, **App. N7**

ESSENTIAL FACILITY

Denial of access to, as anticompetitive conduct under Section 2 of Sherman Act, § 6:8

Diversification and essential facilities doctrine, § 17:10

ETHICAL RESTRAINTS

Generally, § 24:1

Agreements not to engage in competitive bidding, § 24:4

Conclusion, § 24:10

Employee non-compete agreements, § 18:4

INDEX

ETHICAL RESTRAINTS—Cont'd

- Generally applicable antitrust principles, § 24:2
- Limitations on advertising and solicitation, § 24:6
- Membership restrictions, § 24:8
- “Poaching,” limitations on, § 24:5
- Price-fixing agreements, § 24:3
- Restraints on practice form, § 24:7
- Standards of practice relating to quality, § 24:9

“EXAMINING COMPETITION IN GROUP HEALTH CARE”

- Prepared Statement of FTC Before U.S. Senate Committee on Judiciary, (Sept. 6, 2006), **App. E142A**

EXCLUSIONARY CONDUCT

- See also Anticompetitive Conduct (this index)
- Unreasonably, as anticompetitive conduct under Section 2 of Sherman Act, § 6:12

“EXCLUSIONARY VERTICAL AGREEMENTS”

- (Speech), **App. E85**

EXCLUSION FROM FACILITY

- Practitioner Credentialing (this index)

EXCLUSION PAYMENT SETTLEMENTS

- “Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,” prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**
- “Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” prepared remarks before second annual in-house counsel’s forum on

EXCLUSION PAYMENT

SETTLEMENTS—Cont'd

- pharmaceutical antitrust (Apr. 24, 2006), **App. E141**
- “FTC v. Actavis and the Future of Reverse Payment Cases,” remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**
- “How Pay-for-Delay Settlements Make Consumers and Federal Government Pay More for Much Needed Drugs,” prepared statement of J. Thomas Rosch, Commissioner, FTC, before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E168**
- Pay-for-Delay Settlements generally, **25:1, 25:2**
- Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**
- recent cases, **25:2**

EXCLUSIVE CONTRACTS

- Health plan market power, § 21:9
- Hospital/physician. Exclusive Contracts (Hospital/Physician) (this index)
- Physician-owned facilities, § 18:3

EXCLUSIVE CONTRACTS (HOSPITAL/PHYSICIAN)

- Generally, § 14:1
- And vertical price-fixing agreements, § 14:15
- Antitrust theories, § 14:2
- As tying arrangements generally, § 14:3
- conditional sale of one service on purchase of another, § 14:5

**EXCLUSIVE CONTRACTS
(HOSPITAL/PHYSICIAN)**

—Cont’d

- As tying arrangements—Cont’d
 - economic interest in sale of tied product, § 14:8
 - effect on substantial amount of interstate commerce, § 14:7
 - legitimate business justification, § 14:9
 - market power in market for tying product, § 14:6
 - separate and distinct products, § 14:4
- As violations of Section 2 of Sherman Act, § 14:13
- Departmental closings, § 14:14
- Exclusive dealing agreements
 - generally, § 14:10
 - effect on competition, § 14:12
 - relevant market, § 14:11
- Minimizing antitrust risk, § 14:16

**EXCLUSIVE DEALING
AGREEMENTS
(HOSPITAL/PHYSICIAN)**

- Generally, § 14:10
- “Anticompetitive Aspects of Exclusive Dealing and Related Practices” (speech), App. E88
- As vertical agreements under Section 1 of Sherman Act, § 5:7
- Diversification resulting from, § 17:4
- Effect on competition, § 14:12
- Relevant market, § 14:11

EXCLUSIVE JURISDICTION

- Generally, § 9:6

EXEMPTIONS AND IMMUNITIES

- Generally, § 9:1
- Business of insurance, § 9:10
- Federal government and federally regulated industries
 - generally, § 9:3
 - express immunity, § 9:4
 - federal government immunity, § 9:3
 - implied repeal, § 9:5

**EXEMPTIONS AND IMMUNITIES
—Cont’d**

- Federal government and federally regulated industries—Cont’d
 - primary and exclusive jurisdiction, § 9:6
- Health Care Quality Improvement Act, § 9:12
- Hospital medical staff credentialing, § 9:12
- Labor, § 9:11
- Local Government Antitrust Act, § 9:9
- Nonprofit entities and noncommercial conduct, § 9:2
- Physician peer-review activities, § 9:12
- Robinson-Patman Act, § 7:10
- Solicitation of government action, § 9:8
- State action, § 9:7
 - from antitrust, § 9:7
 - mergers, economic effects, § 15:6
 - “Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to Rein in State Action Immunity,” Maureen K. Ohlhausen, Commissioner, (Mar 31, 2015), App. E240

EXPRESS IMMUNITY

- From antitrust, § 9:4

FACILITY

- Denial of access to essential, as anticompetitive conduct under Section 2 of Sherman Act, § 6:8

**FEDERAL COMPLAINT FOR
INJUNCTION**

- FTC v. U.S. Anesthesia Partners, Inc., App. N9

FEDERAL GOVERNMENT

- And federally regulated industries. Exemptions and Immunities (this index)

**FEDERAL TRADE COMMISSION
(FTC)**

- For detailed matters, see more specific entries throughout this index

INDEX

FEDERAL TRADE COMMISSION (FTC)—Cont'd

Generally, **App. B3C, App. B3E**
Accountable Care Organizations,
§ 20:15, **App. H1**
Accountable Care Organizations
participating in Medicare Shared
Savings Program, **App. E215**
Administrative Complaint
Matter of GTCR BC Holdings,
LLC and Surmodics, Inc
FTC Matter/File Number 241
0095, Docket Number
9440, **App. N24**
Adoption of the Statement of
Enforcement Policy, Unfair
Methods of Competition Under
Section 5 of the FTC Act, **App.**
E288
Advanced practice nurses, “Policy
Perspectives: Competition and
Regulation of Advanced Practice
Nurses” FTC Executive Sum-
mary (Mar. 2014), **App. E229**
Advanced practice registered nurses,
advocacy letter regarding, **App.**
D158, App. D169, App. D181
“Advancing Economic Liberty,”
App. E257
Advisory opinions of
for detailed matters, see Advisory
Opinions (this index)
generally, § 10:9
Affiliation agreement, close of
investigation of, **App. E205**
“A Health Care Check on COPAs;
Assessing the Impact of Certifi-
cates of Public Advantage in
Health Care Markets” Joseph J.
Simons, (June 18, 2019), **App.**
E268
Alabama State Board of Medical
Examiners, FTC staff comments
concerning proposed regulation
of interventional pain manage-
ment services, **App. D135**
Alaska House of Representatives,
prepared statement of FTC
concerning certificate of need
(Feb. 15, 2008), **App. E159**

FEDERAL TRADE COMMISSION (FTC)—Cont'd

Alaska Senate Committee on Labor
and Commerce, Certificate-of-
Need Laws and SB 62, state-
ment of FTC (Feb. 6, 2018),
App. E256
Amicus brief, Jazz Pharmaceuticals
v. Avadel CNS Pharmaceuticals,
App. D207
Annual report, 44th Hart-Scott-
Rodino, **App. D209**
“Antitrust Analysis of Reverse Pay-
ments After Actavis: Three
Questions and Proposed
Answers,” text of remarks of
Joshua D. Wright, Commis-
sioner, FTC, before the ABA
Master Course VII (Oct. 10,
2014), **App. E235**
Appeal procedure for requests for
additional information, **App. B8**
Assistant attorney general Jonathan
Kanter announces task force on
health care monopolies and col-
lusion (May 9, 2024), **App. N15**
Attempted merger of Rhode Island’s
largest healthcare providers,
App. E282
“Bigger than Big Tech? The Need to
Reform Our Health Care
Markets Using Choice and
Competition” Christine S.
Wilson, (September 9, 2019),
App. E269
Bureau of Competition. Bureau of
Competition (this index)
Caremark Rx/AdvancePCS merger,
FTC statement in closing
investigation of (Feb. 11, 2004),
App. E127
Certificate-of-need
Alaska Senate Bill 62 (Feb. 6,
2018), **App. D197**
Alaska Senate Committee on
Labor and Commerce, Certifi-
cate-of-Need Laws and SB
62, statement of FTC (Feb. 6,
2018), **App. E256**
application, advocacy letter, **App.**
D195

**FEDERAL TRADE COMMISSION
(FTC)—Cont’d**

- Certificate-of-need—Cont’d
 - laws and Alaska, joint statement of FTC and Antitrust Division (Apr. 7, 2017), **App. D194**
 - laws and Alaska Senate Bill 62 (Feb. 6, 2018), **App. D197**
- Certificates of Public Advantage, advocacy letter regarding, **App. D170**
- Certified nurse practitioners, advocacy letter, **App. D196**
- Chronic pain treatment by certified registered nurse anesthetists, **App. D159**
- “Clinical Integration: The Changing Climate and What It Means for Care Coordination” (Apr. 27, 2009), remarks of Pamela Jones Harbour, Commissioner, FTC, **App. E170**
- Collaborative activity, FTC Staff Advocacy letter to West Virginia concerning state-action protection (Mar. 9, 2016), **App. D183**
- Collaborative practice agreements between advanced practice registered nurses and physicians, **App. D152**
- Competition in health care markets, text of remarks regarding, **App. E218**
- Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E287**
- Competitively sensitive health care information, advocacy letter regarding a bill to permit disclosure, **App. D173**
- Competitive marketplace for biosimilars, FDA/FTC workshop, **App. D208**
- Concurring statement of commissioner Andrew N. Ferguson regarding the pharmacy benefit managers interim staff report (July 9, 2024), **App. N14**

**FEDERAL TRADE COMMISSION
(FTC)—Cont’d**

- Connecticut General Assembly, letter concerning bill to establish provider cooperative care arrangements, **App. D145**
- “Death by a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform,” **App. E258**
- Delaware (this index)
- Dentists and Oral Surgeons (this index)
- Denturists regulation, FTC Advocacy letter to Kentucky House of Representatives (Mar. 25, 2016), **App. D185**
- Divestiture of locations to address concerns regarding proposed acquisition, **App. E212**
- DOJ and FTC Antitrust Guidelines for Business Activities Affecting Workers
 - (January 2025), **App. N26**
- DOJ and FTC 2023 Merger Guidelines, **App. B20**
- DOJ Antitrust Division, Economic analysis group discussion paper
 - Online Reviews and Hospital Choices, EAG 22-1 December 2022, **App. N5**
- “Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,” text of remarks of Martin Gaynor, Director, Bureau of Economics, FTC, before the 2014 American Antitrust Institute Annual Conference, **App. E234**
- Eliminating certain occupational licensing requirements, staff advocacy letter (Mar. 15, 2017), **App. D193**
- Enforcement against illegal mergers, **App. B19**
- Enforcement by
 - generally, **§ 10:7**
 - see also Enforcement (this index)
- FDA draft guidance biosimilar drugs comment letter (August 20,

INDEX

FEDERAL TRADE COMMISSION (FTC)—Cont'd

- 2024), **App. N16**
- FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D208**
- Florida House of Representatives, letter concerning regulation of advanced registered nurse practitioners, **App. D140**
- 44th Hart-Scott-Rodino annual report, **App. D209**
- FTC amicus brief
re Bystolic Antitrust Litigation, **App. D211**
- Georgia Board of Dentistry, FTC comments concerning proposed amendments to rules governing supervision of hygienists, **App. D136**
- Hart-Scott-Rodino annual report, 44th, **App. D209**
- Health care hospitals collaboration, advocacy letter regarding authorization, **App. D172**
- Health care information exchanges, advocacy letter regarding proposed antitrust immunity, **App. D171**
- “Health Care Technology: Promoting Competition and Protecting Innovation,” Maureen K. Ohlhausen, Commissioner, before Connecticut Bar Association Antitrust amp: Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E228**
- Health information technology, advocacy letter regarding interoperability, **App. D168**
- “Hospital Consolidation: The Good, The Bad, and The Ugly,” **App. E214**
- HSR, FAQ, **App. B12**
- HSR premerger, withdrawal and refiling, **App. B13**
- Human resource professionals, DOJ and FTC antitrust guidance (Oct. 2016), **App. J1**

FEDERAL TRADE COMMISSION (FTC)—Cont'd

- Illinois State Senate, letter concerning limiting chronic pain treatment by certified registered nurse anesthetists, **App. D159**
- “Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care” Prepared Statement of FTC before Senate Subcommittee on Consumer Protection, Product Safety, and Insurance (July 16, 2009), **App. E172**
- In re Davita, proposed order, re-instituted use of prior approval provisions in merger orders, **App. 18**
- Interim staff report on pharmacy benefit managers
the powerful middlemen inflating drug costs and squeezing main street pharmacies (July 2024), **App. N11**
- J. Thomas Roche, Antitrust/Intellectual Property Interface, **App. E184**
- J. Thomas Roche, letter concerning antitrust ramifications of accountable care organizations, **App. D138**
- Kentucky Cabinet for Health and Family Services, FTC staff comments concerning proposed rule to regulate limited service clinics, **App. D133**
- Kentucky State Senate, letter concerning bill relating to advanced practice registered nurses scope of practice, **App. D150**
- Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E286**
- Lifespan Corporation and Care New England Health System, statement, **App. E281**
- “Looking Back to Move Forward: Preserving the Progressive Tradition at the FTC,” **App. E213**

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- Louisiana State Representatives, letter concerning Registered Nurse Collaborative Agreements (Apr. 20, 2012), **App. D152**
- Maine Board of Dental Examiners, letter concerning proposed rule to limit x-ray procedures by dental hygienists, **App. D149**
- Massachusetts House of Representatives, letter concerning removal of supervision requirement from nurse practitioners and nurse anesthesiologists (Jan. 17, 2014), **App. D162**
- Medical school collaboration agreements, letter to Alabama State Senate concerning antitrust exemption for public university medical school agreements (May. 2, 2016), **App. D186**
- Medicare Prescription Drug Benefit Programs, Staff Advocacy Letter to Centers for Medicare and Medicaid Services concerning any-willing-provider changes (Mar. 7, 2014), **App. D164**
- Memorandum of Agreement between FTC and Antitrust Division of the U.S. Dept. of Justice concerning clearance procedures for investigations, **App. B7**
- Mergers and
 - generally, § 15:3
 - Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**
 - consent orders, FAQ, § 15:36
 - guidelines on horizontal mergers, § 15:9, **App. B6**
 - “Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- Mergers and—Cont'd
 - staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation’s proposed acquisition of Slidell Memorial Hospital (Apr. 1, 2003), **App. D101**
 - statement on horizontal mergers (1982), **App. B2**
- Minnesota House of Representatives, FTC Staff advocacy letter regarding bill to permit disclosure of competitively sensitive health care information, **App. D173**
- Mississippi House of Representatives, letter concerning regulation of pharmacy benefit managers, **App. D141**
- Missouri House of Representatives, letter concerning bill relating to CRNA scope of practice, **App. D151**
- Multilateral pharmaceutical merger task force, Commissioner statement, **App. E276**
- Multilateral pharmaceutical merger task force, public input, press release, **App. D202**
- New Jersey Hospital Networks merger, **App. E283**
- New York, staff comment on proposal to allow licensure by endorsement of Canadian dental licenses, **App. D199**
- New York Senate, comment concerning regulation of mail-order pharmacies, **App. D146**
- New York Senate, letter concerning bill to permit collective negotiations among providers, **App. D148**
- New York State Assembly, FTC Staff advocacy letter regarding authorization of health care hospitals collaboration, **App. D172**
- Non-Profit Institutions Act
 - Community CarePartners, staff

INDEX

FEDERAL TRADE COMMISSION (FTC)—Cont'd

- Non-Profit Institutions Act—Cont'd
advisory opinion to, **App. D132**
 - Quest Analytics Group, staff advisory opinion to, **App. D165**
 - University of Michigan, staff advisory opinion to the, **App. D131**
- Non-Profit Institutions Act, opinion concerning, **App. D155, App. D156**
- Norman Physician Hospital Organization, Staff Advisory Opinion to, **App. D157**
- North Carolina House of Representatives, FTC Staff advocacy letter concerning a bill to modify Certificate-of-Need law (July 10, 2015), **App. D174**
- North Carolina Senate Bill 743
state action defense to UNC
healths collaborative activities, **App. D210**
- North Carolina State Board of Opticians, FTC staff comments concerning proposed regulations for optical goods and optical goods business, **App. D137**
- Nurse practitioners and nurse anesthesiologists, Staff letter to Hon. Kay Khan, Massachusetts House of Representatives, concerning bill to remove supervision requirement (Jan. 17, 2014), **App. D162**
- Office of Public Affairs Director, preliminary injunction halting New Jersey hospital merger, **App. E278**
- Orange book, brand drug manufacturers improper listing of patents, statement, **App. B22**
- Order to file a special report, **App. D203**
- Oregon Legislature, FTC Staff advocacy letter concerning antitrust immunity for health care information exchanges

FEDERAL TRADE COMMISSION (FTC)—Cont'd

- (May 18, 2015), **App. D171**
- “Oversight of Enforcement of Antitrust Law,” prepared statement of FTC before U.S. Senate Committee on the Judiciary (Mar 9, 2016), **App. E251**
- “Oversight of Enforcement of Antitrust Laws,” Edith Ramirez before U.S. House of Representatives, Washington D.C. (Nov 15, 2003), **App. E226**
- Overview of FTC actions in health care services and products (December 2025), **App. L1**
- Overview of FTC actions in pharmaceutical products and distribution (December 2025), **App. L2**
- Pay-for-delay deals, limiting competition and costing consumers, **App. E219**
- “Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**
- PBM related advocacy and current market realities reports, **App. D212**
- Perspectives on Certificates of Public Advantage, **App. D205**
- Petition
 - FTC v. Louisiana Childrens Medical Center, **App. N6**
- Pharmaceutical merger enforcement program, Commissioner statement, **App. E275**
- Pharmaceutical mergers, analysis examination, **App. N4**
- Pharmaceutical Task Force Workshop, keynote remarks of Commissioner Rebecca Kelly Slaughter, **App. E286**

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- Physician collaboration, letter concerning proposed legislation, **App. D160**
- Post-patent pharmaceutical markets, issues in, **App. E260**
- Preliminary injunction pursuant to Section 13(b) of the Federal Trade Commission Act, **App. N2**
- Prepared Remarks Before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**
- Prepared Statement Before Committee of Small Business, U.S. House of Representatives on “Competition and Potential Costs and Benefits of Professional Licensure” (Jul. 16, 2014), **App. E238**
- Prepared Statement Before Florida State Senate on health care competition and Florida’s certificate of need (CON) laws (Apr. 2, 2008), **App. E163**
- Prepared Statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives on Pay-for-Delay Settlements (Mar. 31, 2009)—J. Thomas Rosch, Commissioner, FTC, **App. E168**
- Prepared Statement before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate on Anticompetitive Pay-for-Delay Settlements (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**
- Prepared Statement Before U.S. Senate Committee on Judiciary, “Examining Competition in Group Health Care” (Sept. 6, 2006), **App. E142A**
- Prepared Statement Before U.S. Senate Committee on the Judiciary,

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- “License to Compete: Occupational Licensing and the State Action Doctrine” (Feb. 2, 2016), **App. E249**
- Prepared Statement Before U.S. Senate Special Committee on Aging Concerning Barriers to Generic Entry (July 20, 2006), **App. E142**
- Prepared Statement of FTC and Pharmaceutical Industry before Committee of Judiciary, US Senate (June 17, 2003)—Timothy J. Muris, Chairman, FTC, **App. E121**
- Press release, FTC, DOJ and HHS work lower health care and drug costs, **App. B21**
- Primary service area shares under ACO policy statement, calculating, **App. E216**
- Protecting competition in healthcare markets, **App. E261**
- Provider-controlled contracting networks, Federal Trade Commission and Department of Justice Statement of Antitrust Enforcement Policy, § 20:15
- Quest Analytics Group, FTC Staff advisory opinion concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D165**
- Requests for additional information, appeal procedure for, **App. B8**
- “Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez, Chairwoman, before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**
- Richard A. Feinstein statement to House committee on antitrust enforcement in the health care industry, **App. E185**
- Second-request form letter, **App. B3H**

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- “Section 5: Principles of Navigation,” Maureen K. Ohlhausen, Commissioner, before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E220**
- Sharon a. Pozen statement before Judiciary Committee on antitrust, competition policy, and consumer rights, **App. E186**
- South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**
- South Carolina House of Representatives, joint statement of FTC and Antitrust Division on Certify-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D179**
- Staff Comment
North Carolina Senate Bill 743, **App. D210**
- Staff comment on New York’s proposal to allow licensure by endorsement of Canadian dental licenses, **App. D199**
- Staff comment to Washing State Rep. Paul Graves, S.S.B. 5411/H.B. 1473 (Feb. 9 2018), **App. D198**
- Staff letter to Hon. Elaine Nekritz, Illinois State Representative, concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D124**
- Staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**
- Staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation’s proposed acquisition of Sliddell Memorial Hospital (Apr. 1, 2003), **App. D101**
- Staff letter to Louisiana State Representative Timothy G. Burns

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- concerning in-house school dentistry (May 1, 2009), **App. D128**
- Staff letter to Minnesota State Representative Tom Emmer concerning rural health care cooperatives joint negotiation (Mar. 18, 2009), **App. D125**
- Staff letter to North Carolina representative concerning dental practice managers (May 25, 2012), **App. D153**
- Staff letter to Ohio House of Representatives (Oct. 16, 2002), **App. D97**
- Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D121**
- Staff letter to Rep. Patrick McHenry Concerning Proposed Bill Regulating Pharmacy Benefit Manager Contractual Relationships (Jul. 15, 2005), **App. D111**
- Staff letter to Senator James L. Seward, New York Senate, concerning pharmacy-benefit-manager regulation (Mar. 31, 2009), **App. D126**
- Staff letter to Tennessee senate concerning bill regulating optometry (Apr. 29, 2003), **App. D102**
- Staff opinion letter to TriState Health Partners (Apr. 13, 2009), **App. D127**
- State Action Doctrine, **App. E210**
- Statement before Joint Committee on Health, West Virginia Legislature, **App. E207**
- Statement of, second circuit order Pharma Bro Martin Shkrelis lifetime ban, upholding, **App. B25**
- Statement of chair Lina M. Khan joined by commissioners alvaro m. bedoya & rebecca kelly slaughter regarding the

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- pharmacy benefit managers
interim staff report (July 9,
2024), **App. N12**
- Statement of commissioner Rebecca
Kelly slaughter regarding ftc
staff interim report
pharmacy benefit managers
(August 1, 2024), **App. N13**
- Statement of FTC Bureau of Compe-
tition Deputy Director Rahul
Rao on Lawsuit Against PBMs
and the Role of Drug
Manufacturers in Distorting
Competition in the U.S Drug
Distribution System (September
20, 2024), **App. N18**
- Statement of Richard A. Feinstein,
FTC Bureau of Competition, on
the FTC's Closure of its
Investigation of Consummated
Hospital Merger in Temple,
Texas (Dec. 23, 2009), **App.
E175**
- Statement of the Federal Trade Com-
mission's Bureau of Competi-
tion on Guidelines for Merger
Investigations (Dec. 11, 2002),
App. B3F
- State of Rhode Island v. Lifespan
Corporation and Care New
England Health System, state-
ment, **App. E279**
- Study on pharmacy benefit managers,
chair remarks, **App. E280**
- Supplemental Staff Submission to
Indiana Health Staff Submission
to Indiana Health
Department Regarding 2025, Cer-
tificate of Public Advantage
Application of Union Health and
Terre Haute Regional
Hospital (March 17, 2025),
App. N25
- Telehealth services, FTC Advocacy
letter to Alaska State Legislature
concerning (Mar. 25, 2016),
App. D184
- Temporary restraining order
pursuant to Section 13(b) of the

**FEDERAL TRADE COMMISSION
(FTC)—Cont'd**

- Temporary restraining order—Cont'd
Federal Trade Commission
Act, **App. N2**
- Tennessee House of Representatives,
letter concerning bill to regulate
pain management services, **App.
D147**
- Tennessee Legislature, letter concern-
ing repeal of state-action exemp-
tion legislation for Tennessee
public hospitals, **App. D144**
- Texas House of Representatives, let-
ter concerning bill to permit
health care collaboratives, **App.
D143**
- Texas State Board Examiners, Staff
advocacy letter to Simone Sal-
loun, concerning proposed rules
(Oct. 14, 2014), **App. D166**
- Texas State Senate, letter concerning
regulation of advanced
registered nurse practitioners,
App. D142
- Treatment of debt as consideration,
App. B16
- Under Section 7 of Clayton Act,
§ 8:18
- “Unfair Methods of Competition”
under Section 5 of FTC Act,
statement of enforcement
principles regarding (Aug. 13,
2015), **App. I1**
- Unfair Methods of Competition
Under Section 5 of the FTC Act,
Adoption of the Statement of
Enforcement Policy, **App. E288**
- Unfair trade practices, “Section 5:
Principles of Navigation” (July
25, 2013), **App. E220**
- United States Senate Committee on
the Judiciary Subcommittee on
Antitrust, **App. E287**
- Use of prior approval provisions in
merger orders, **App. B17**
- U.S. Senators, letter concerning
antitrust and accountable care
organizations, **App. D139**

INDEX

FEDERAL TRADE COMMISSION (FTC)—Cont'd

Vertically Integrated Pharmacy
Specialty Generic Drugs
Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers (January 14, 2025), **App. N22**

Veterans Administration, advocacy letter, advanced practice registered nurses restrictions (July 25, 2016), **App. D188**

Virginia Certificate of Need Work Group, joint statement of FTC and Antitrust Division (Oct. 26, 2015), **App. D177**

“What’s Past is Prologue: FTC’s Competition and Consumer Protection Priorities,” text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**

Workshop summary
Pharmaceutical mergers, analysis examination, **App. N4**

FEDERAL TRADE COMMISSION, PLAINTIFF, V. SURESCRIPTS, LLC

Stipulated order for, equitable relief and permanent injunction, **App. N7**

FEDERAL TRADE COMMISSION ACT

Generally, § 7:13

Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**

Text of, excerpts, **App. A5**

FEES

FTC Staff letter to Puerto Rico Treasury and Financial Affairs Committee objecting to bill permitting health-care providers to collectively negotiate fees (Jan. 30, 2008), **App. D121**

FEINSTEIN, DEBORAH L.

“Antitrust Enforcement in Health Care: Proscription, Not Prescription,” remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC, before the Fifth National Accountable Care Organization Summit (June 19, 2014), **App. E232**

“The Forward-Looking Nature of Merger Analysis,” remarks by Deborah L. Feinstein, Director, Bureau of Competition, FTC (Feb. 6, 2014), **App. E230**

FINAL DECISION AND ORDER

Welsh, Carson, Anderson & Stowe, in matter of, **App. N29**

FINANCIAL RISK SHARING

Provider-controlled contracting networks, antitrust safety zones, § 20:5

FIRMS

See also Business (this index)

FIRST LOOK, LLC

Advisory opinions (June 19, 1997), **App. D77**

FIRST PRIORITY HEALTH

Business review letters (Nov. 3, 1997), **App. C84**

FISCAL YEAR 2024

Hart-Scott-Rodino Annual Report, **App. D213**

FLORIDA STATE SENATE

Federal Trade Commission prepared statement concerning certificate of need laws (Apr. 2, 2008), **App. E163**

FOLLOW-ON BIOLOGICS

Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner,

FOLLOW-ON BIOLOGICS

—Cont'd

FTC (Nov. 19, 2009), **App. E174**

FOOD AND DRUG

ADMINISTRATION (FDA)

Antitrust implications, listing a drug in Orange Book, **26:1**

FDA/FTC workshop

competitive marketplace for biosimilars, **App. D208**

opening remarks of Chairman Joseph Simons, **App. E271**

Statement, collaboration to advance competition in biologic marketplace, **App. F6**

FORMAN, ANDREW

Keynote speech, **App. E284**

**FOUNDATION FOR THE
ACCREDITATION OF
HEMATOPOIETIC CELL
THERAPY**

Advisory opinions (Apr. 17, 1997), **App. D74**

FRIMET, GILBERT M.

Advisory opinion, **App. D8**

FTC

Generally. Federal Trade Commission (FTC) (this index)

**FTC AGREEMENT CONSENT
ORDER**

Gateway Services, Inc. and Gateway US Holdings, Inc., **App. F8**

FTC AMICUS BRIEF

Re Bystolic Antitrust Litigation, **App. D211**

FTC CLARKE EDWARDS LETTER

Senator Brad Hutto, **App. D214**

FTC COMPLAINT

In the Matter of Centerbridge Seaport Acquisition Fund, L.P., **App. F12**

**FTC HEALTHCARE
NON-COMPETE**

Warning Letter Template, **App. F11**

**FTC NON-COMPETE
COMPLAINT**

Gateway Services, Inc. & Gateway US Holdings, Inc., **App. F7**

**FTC V. LOUISIANA CHILDRENS
MEDICAL CENTER,**

Petition, **App. N6**

**FTC V. U.S. ANESTHESIA
PARTNERS, INC.**

Federal complaint for injunction, **App. N9**

FUNDAMENTAL CONCEPTS

Of Section 1, Sherman Act. Sherman Act (this index)

GALES REXALL DRUG

Business review letter, **App. C1**

**GASTROENTEROLOGY
ASSOCIATES, LTD**

Business review letters (July 7, 1997), **App. C82**

**GATEWAY PET MEMORIAL
SERVICES**

Andrew N. Ferguson & Melissa Holyoak Statement, **App. F9**

**GATEWAY SERVICES, INC. &
GATEWAY US HOLDINGS,
INC.**

FTC Agreement Consent Order, **App. F8**

FTC Non-Compete Complaint, **App. F7**

GAYNOR, MARTIN

“Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,” text of remarks before the 2014 American Antitrust Institute Annual Conference, **App. E234**

GENERIC DRUGS

“How Pay-for-Delay Settlements Make Consumers and the

INDEX

GENERIC DRUGS—Cont’d

Federal Government Pay More for Much Needed Drugs,” prepared statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E168**

Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**

GEORGE MASON SCHOOL OF LAW

“Brother, May I? The Challenge of Competitor Control over Market Entry” remarks of Maureen K. Ohlhausen, Commissioner, before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E243**

GEORGETOWN GLOBAL ANTITRUST SYMPOSIUM

“The FTC’s Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,” Joshua D. Wright, Washington, D.C. (Sept. 24, 2013), **App. E223**

GEORGE WASHINGTON UNIVERSITY LAW SCHOOL

“Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez, Chairwoman, FTC, at the Merger Transactions Symposium (June 28, 2013), **App. E233**

GEORGIA GENERAL ASSEMBLY

U.S. Department of Justice Antitrust Division, “Competition in healthcare and certificate of

GEORGIA GENERAL ASSEMBLY—Cont’d

need” (Feb. 23, 2007), **App. E145**

GEORGIA PREFERRED PODIATRIC MEDICAL NETWORK

Business review letters (Nov. 3, 1995), **App. C58**

GEORGIA STATE SENATE

FTC Advocacy letter to Hon. Valencia Seay concerning supervision of dental hygienists (Jan. 29, 2016), **App. D180**

GERMANY

“Protecting Consumer Welfare in the U.S. Health Care Sector,” before the Mentor Group Forum for EU-US Legal-Economic Affairs, Berlin, Germany (Sept 13, 2013), **App. E221**

GI ASSOCIATES, P.C.

Business review letters (July 7, 1997), **App. C82**

GLOBAL ANTITRUST ECONOMICS CONFERENCE AND SYMPOSIUM

“Brother, May I? The Challenge of Competitor Control over Market Entry” remarks of Maureen K. Ohlhausen, Commissioner, before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E243**

“The Horizontal Merger Guidelines Five Years Later” text of remarks of Edith Ramirez before Georgetown University Law Center Ninth Symposium (Sept. 29, 2015), **App. E247**

GOVERNMENT ENFORCEMENT STATEMENTS

Antitrust laws, § 1:7

GOVERNMENT JUDGMENTS

Effect of, in damage actions, § 11:14

**GREATER ROCHESTER
INDEPENDENT PRACTICE
ASSOCIATION**

Advisory opinions (Sept. 17, 2007),
App. D119

**GROUP PURCHASING
PROGRAMS**

Analyzing, § 16:8

“U.S. v. AzHAA: When Does a
Group Purchasing Organization
Become an Illegal
Monopsonist?,” prepared
remarks before AHLA annual
meeting (June 26, 2007), **App.
E151**

GUIDELINES

Federal government antitrust
guidelines, § 1:8

**“GUIDEPOSTS IN THE
ANALYSIS: THE FEDERAL
TRADE COMMISSION AND
U.S. DEPARTMENT OF
JUSTICE, ANTITRUST
DIVISION COMPETITOR
COLLABORATION
GUIDELINES”**

(Speech), **App. E92**

**HAL WHITE ANTITRUST
CONFERENCE**

“Competition in Health Care
Markets,” text of remarks by
Julie Brill, Commissioner, FTC,
at 2014 Conference (June 9,
2014), **App. E231**

**HANGER ORTHOPEDIC GROUP,
INC.**

Business review letters (Sept 15,
1995), **App. C55**

HARBOUR, PAMELA JONES

“A ‘Check-Up’ of Selected Health
Care Activity at FTC,” remarks
before ABA antitrust law spring
meeting (Mar. 30, 2005), **App.
E132**

HART-SCOTT-RODINO ACT

Generally, **App. B3D**

**HART-SCOTT-RODINO ANNUAL
REPORT**

Fiscal Year 2024, **App. D213**
44th, FTC and Department of Justice,
App. D209

**HARVARD VANGUARD MEDICAL
ASSOCIATES, INC.**

Advisory opinions (Dec. 18, 2001),
App. D90

**HEALTH AND PERSONAL CARE
CONFERENCE, INC.**

Business review letter, **App. C34**

**“HEALTH CARE GUIDELINES
AND ASSOCIATIONS, HOW
ASSOCIATIONS CAN WORK
WITH THE DEPARTMENT OF
JUSTICE”**

(Speech), **App. E36**

**HEALTH CARE INFORMATION
EXCHANGES**

Federal Trade Commission staff
advocacy letter to Sen. Chip
Shields, Oregon State
Legislature concerning antitrust
immunity (May 18, 2015), **App.
D171**

**HEALTH CARE MANAGEMENT
ASSOCIATES**

Advisory opinion, **App. D3**
Business review letter, **App. C14**

HEALTH CARE MARKETS

“Thoughts on ‘Leveling the Playing
Field’ in Health Care Markets”
(speech), **App. E73**

**HEALTH CARE QUALITY
IMPROVEMENT ACT**

Antitrust exemptions, § 9:12
Practitioner credentialing and, § 9:12,
§ 13:8
Text of, **App. A8**

HEALTHCARE SUMMIT

“Enforcement Strategies in the
Health Care Industry,” prepared
remarks of J. Thomas Rosch
before ABA Health Law Section

INDEX

HEALTHCARE SUMMIT—Cont’d
Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**

HEALTH CARE TECHNOLOGY
“Health Care Technology: Promoting Competition and Protecting Innovation,” Maureen K. Ohlhausen, Commissioner of FTC, before Connecticut Bar Association Antitrust and Trade Regulation and Consumer Law Sections (Feb. 26, 2014), **App. E228**

HEALTH COVERAGE, INSURANCE, AND FINANCIAL SERVICES
LD 97 supporting testimony
Division Director, Licensing & Certification at State of Maine, **App. N3**

HEALTH DEPARTMENT
Staff Submission to Indiana Health Department Regarding the Certificate of Public Advantage Application of Union Health and Terre Haute Regional Hospital (September 5, 2024), **App. N19**

HEALTH INFORMATION TECHNOLOGY
FTC Staff advocacy letter to Department of Health and Human Services concerning interoperability (Apr. 3, 2015), **App. D168**

HEALTH PLAN MARKET POWER
Generally, § 21:1
All-products provisions and payer monopoly power, § 21:7
Exclusions from providers from health plans or contracting networks, generally, § 21:8, § 21:9
Exclusive contracting, § 21:9
Low reimbursement and payer monopoly power, § 21:5
McCarran-Ferguson Act’s effects, generally, § 21:2

HEALTH PLAN MARKET POWER—Cont’d

Monopsony power. See Payer monopsony power, below
Most-favored-nations provisions and payer monopoly power, § 21:6
Networks, provider exclusions from. See entries throughout this topic
Participation agreements between providers and payers, § 21:3
Payer monopsony power
generally, § 21:4 to 21:7
all-products provisions and, § 21:7
low reimbursement and, § 21:5
most-favored-nations provisions and, § 21:6
Provider exclusions from networks. See entries throughout this topic
Reimbursement and payer monopoly power, low reimbursement, § 21:5
Selective and exclusive contracting, § 21:9

HEALTH-PLAN MERGERS
Mergers, § 15:33

HEALTH PLANNING
Market-allocation agreements and. Market-Allocation Agreements (this index)

HEALTH PLANNING ACT
Antitrust laws and, § 22:2

HEMATOLOGY/ONCOLOGY CARE SPECIALISTS OF WESTERN PENNSYLVANIA, P.C.

Advisory opinions (Sept. 21, 1995), **App. D56**

HENRY COUNTY MEMORIAL HOSPITAL

Advisory opinions (Apr. 10, 1997), **App. D76**

HERITAGE ALLIANCE AND LACKAWANNA PHYSICIANS ORGANIZATION

Business review letters (Sept. 15, 1998), **App. C86**

HIGHLY INNOVATED INDUSTRIES

“Mergers that Increase Bargaining Leverage,” Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, before Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E227**

HISTORY

Of antitrust laws, § 1:3
Of enforcement in health care sector, § 1:6

HMO EXCLUSIVE CONTRACTS

Advisory opinion, **App. D24**

HOME CARE ALLIANCE, INC.

Business review letters (Oct. 4, 1996), **App. C73**

HOME CARE PROVIDERS

FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**

HOME HEALTH INVESTIGATION

Vermont, U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

HOME HEALTH SERVICES ACT OF 2005

U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

HORIZONTAL AGREEMENTS

“A Stepwise Approach to Antitrust Review of Horizontal Agreements” (speech), **App. E69**

Under Section 1 of Sherman Act generally, § 4:1, § 4:4
agreements to exchange or disseminate information, § 4:3
bid-rigging agreements, § 4:5

HORIZONTAL AGREEMENTS

—Cont’d

Under Section 1 of Sherman Act
—Cont’d
concerted refusals to deal, § 4:7
covenants not to compete, § 4:6
health planning activities and, § 22:5
horizontal market-allocation agreements, § 4:4
horizontal price-fixing agreements, § 4:2
mergers and joint ventures, § 4:8
standard-setting programs, § 4:10
unfair competition and dirty tricks, § 4:9

HORIZONTAL MERGERS

Department of Justice and Federal Trade Commission guidelines, § 15:9, **App. B1**
Department of Justice business review procedure, **App. B4**
FTC advisory opinions procedure, **App. B5**
FTC statement on (1982), **App. B2**
Guidelines, Department of Justice and FTC, § 15:9, **App. B1**
1984 Department of Justice guidelines, **App. B6**
“The Horizontal Merger Guidelines Five Years Later” text of remarks of Edith Ramirez before Georgetown University Law Center Ninth Annual Global Antitrust Enforcement Symposium (Sept. 29, 2015), **App. E247**
Under Section 7 of Clayton Act generally, § 8:5
collusion, market characteristics and ease of, § 8:10
concentration, § 8:6
defenses, § 8:13
efficiencies from merger, § 8:12
entry into market, § 8:9
financial viability, § 8:11
other factors, § 8:7
rebuttal evidence, generally, § 8:8 to 8:12

INDEX

HOSPICE NETWORK OF NEW JERSEY, INC.

Business review letters (April 24, 1996), **App. C67**

HOSPITAL CONSOLIDATION

Statement before Committee on the Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer Rights, **App. E277**

HOSPITAL CORPORATION OF AMERICA

Business review letter, **App. C15**

HOSPITAL ORGANIZATION

Credentialing process and generally, § **13:2**
see also Practitioner Credentialing (this index)

HOSPITALS

See more specific entries throughout this index

HOTEL EMPLOYEES AND RESTAURANT EMPLOYEES INTERNATIONAL UNION WELFARE FUND

Business review letter, **App. C41**

HOUSTON HEALTH CARE COALITION

Business review letter, **App. C39**

HUMAN RESOURCES

DOJ and FTC antitrust guidance (Oct. 2016), **App. J1**

HYATT OTT & BLOUNT, P.C.

Business review letter, **App. C28**

IDENTIFICATION

Competitor, mergers and, § **15:12**

ILLINOIS STATE REPRESENTATIVE

Letter from FTC concerning proposed regulation of retail health care facilities (May 29, 2008), **App. D124**

IMMUNITIES

Exemptions and Immunities (this index)

IMPLIED REPEAL

Of antitrust laws, § **9:5**

INDEPENDENT DRUG WHOLESALERS GROUP

Business review letter, **App. C23**

INDIANA HEALTH DEPARTMENT

Supplemental Staff Submission to Indiana Health Staff Submission to
2025, Certificate of Public Advantage
Application of Union Health and Terre Haute Regional Hospital (March 17, 2025), **App. N25**

INFORMATION

Under Section 1 of Sherman Act, § **4:3**

INJUNCTION

FTC v. U.S. Anesthesia Partners, Inc., federal complaint, **App. N9**

INJUNCTIVE RELIEF

In damage actions, § **11:15**

INJURY

Antitrust, as element of damage action, § **11:6**
In damage actions, § **11:3**
In private treble-damage litigation under Robinson-Patman Act, § **7:11**

IN PARI DELICTO DEFENSE

In damage actions, § **11:11**

IN-SCHOOL DENTISTRY

FTC staff letter to Hon. Timothy G. Burns, Louisiana House of Representatives, concerning in-school dentistry (May 1, 2009), **App. D128**

INSURANCE

Business of, antitrust exemption, § **9:10**

“INTEGRATED JOINT VENTURES”

(Speech), **App. E57**

INTENT

Purpose or. Purpose or Intent (this index)

Specific, to monopolize, under Section 2 of Sherman Act, § **6:14**

INTERLOCKING DIRECTORIES

Generally, § **7:1**

INTERNATIONAL CHIROPRACTORS ASSOCIATION

Business review letter, **App. C3**

INTERSTATE COMMERCE

Effect on substantial amount of, exclusive contracts and, § **14:7**

Mergers and, § **15:7**

Practitioner credentialing and, § **13:5**

Subject matter jurisdiction, § **2:2**

INTRACORP

Advisory opinion, **App. D26**

INVESTIGATIONS

Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**

Consummated hospital merger in Temple, Texas, statement of Richard A. Feinstein, Competition Director, FTC Bureau of Competition, on FTC’s closure of investigation of (Dec. 23, 2009), **App. E175**

FTC enforcement, § **10:8**

Memorandum of Agreement between FTC and Antitrust Division of the U.S. Dept. of Justice concerning clearance procedures for investigations, **App. B7**

Premerger, § **15:8**

Protocol for coordination in merger investigations between federal enforcement agencies and state attorneys general, **App. B3G**

INVESTIGATIONS—Cont’d

Vermont, U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

INVESTMENT INTERESTS

Physician-Owned Facilities (this index)

ITASCA CLINIC AND GRAND RAPIDS MEDICAL ASSOCIATES

Business review letters (March 19, 1996), **App. C65**

JAZZ PHARMACEUTICALS V. AVADEL CNS PHARMACEUTICALS

FTC amicus brief, **App. D207**

JOINT VENTURES

Generally, § **16:1**

Analyzing agreements relating to operation of, § **16:5**

Analyzing formation of, § **16:4**

Analyzing particular generally, § **16:7**

group purchasing programs, § **16:8**

joint venture among competitors to provide new services, expensive equipment, and specialized services, § **16:9**

joint ventures between hospitals and physicians, § **16:10**

Classifications of, § **16:3**

Collaboration Guidelines, overview of, § **16:6**

Definition of, § **16:2**

“Integrated Joint Ventures” (speech), **App. E57**

Physician-owned facilities, § **18:3**

Practical factors and danger signals in, § **16:11**

Provider-Controlled Contracting Networks (this index)

Under Section 7 of Clayton Act, § **8:16**

Under Section 1 of Sherman Act, as horizontal agreements, § **4:8**

INDEX

“JOINT VENTURES IN EVOLVING HEALTH CARE MARKETS”

(Speech), **App. E34**

JUDICIARY SUBCOMMITTEE ON ANTITRUST

United States Senate Committee,
Competition Policy and
Consumer Rights Oversight of
the Enforcement of the Antitrust
Laws, **App. E287**

JURISDICTION

Primary and exclusive, § 9:6

JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)

Generally, **App. B3A, App. B3B**

See also more specific entries
throughout this index

Accountable Care Organizations,
statement of antitrust enforce-
ment policy regarding, **App. H1**

Additional information, documentary
material request, **App. B9**

Antitrust healthcare matters resolved
without a case filed, **App. N1**

Arbitration and case selection, guid-
ance, **App. B11**

Business review procedure of
generally, § 10:6, **App. B4**
see also Business Review Letters
(this index)

Certificate-of-need laws and Alaska,
joint statement of FTC and
Antitrust Division (Apr. 7,
2017), **App. D194**

DOJ and FTC joint antitrust state-
ment regarding COVID-19
(March 2020), **App. K1**

Enforcement by. Enforcement (this
index)

FTC and DOJ FAQ, voluntary
expedited review, statement of
Antitrust Enforcement Policy
Regarding ACOs, Medicare
Shared Savings Program, **App.
F5**

JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)—Cont’d

Guidelines on mergers

generally, **App. B1**

horizontal mergers, § 15:9, **App.
B6**

Health care business review letters.
Business Review Letters (this
index)

Human resource professionals, DOJ
and FTC antitrust guidance (Oct.
2016), **App. J1**

Joint DOJ/FTC letter to Alaska on
CON laws (March 11, 2019),
App. F4

Joint DOJ/FTC letter to Tennessee on
CON laws (March 7, 2019),
App. F3

Joint FDA-FTC statement, collabora-
tion to advance competition in
the biologic marketplace (Febru-
ary 3, 2020), **App. F6**

Letter, Maryland, board certification
of medical physicians
(September 10, 2018), **App. F2**

Matters resolved without a case filed,
App. M2

Mergers and, § 15:9, **App. B1, App.
B6**

“Mergers that Increase Bargaining
Leverage,” Aviv Nevo, Deputy
Assistant Attorney General for
Economics, Antitrust Division,
before Stanford Institute for
Economic Policy Research and
Cornerstone Research Confer-
ence on Highly Innovated
Industries (Jan. 22, 2014), **App.
E227**

“Origin of the Species: The 100 Year
Evolution of the Clayton Act,”
text of remarks of William J.
Baer, Assistant Attorney Gen-
eral, Antitrust Division, before
the ABA Clayton Act 100th
Anniversary Symposium (Dec.
4, 2014), **App. E237**

Summary of business reviews, **App.
C109**

JUSTICE DEPARTMENT (UNITED STATES DEPARTMENT OF JUSTICE; ANTITRUST DIVISION)—Cont'd

Summary of health care cases (Since August 25, 1983) (2020), **App. M1**

Under Section 7 of Clayton Act, **§ 8:18**

Vermont, U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

KAISER FOUNDATION HEALTH PLAN

FTC staff advisory opinion to Kaiser Foundation Health Plan (Feb. 13, 2008), **App. D122**

KENTUCKY HOUSE OF REPRESENTATIVES

Denturists, FTC Advocacy letter concerning regulation (Mar. 25, 2016), **App. D185**

KHAN, LINA M.

Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**

Study on Pharmacy Benefit Managers, **App. E280**

KITSAP PHYSICIANS SERVICE

Advisory opinions
March 26, 1984, **App. D9**
May 22, 1984, **App. D11**

LABOR

Antitrust exemption, **§ 9:11**

LD 97

Supporting testimony
Division Director, Licensing & Certification at State of Maine, **App. N3**

LEGISLATIVE CHANGES

Antitrust laws, **§ 1:7**

LEGISLATIVE EXEMPTION

Physician collective bargaining, letter from FTC to Insurance Committee, Ohio House of Representatives, **App. D95**

LETTER

Letter from Office of Policy Planning Acting Director Clarke Edwards to Senator Juan Barnett Concerning Mississippi H.B. 1057 to Address the Practice of Advanced Practice Registered Nurses (January 25, 2026), **App.F15**

Letter to Azurity Pharmaceuticals, **App.N32**

LEVERAGING

Under Section 2 of Sherman Act as anticompetitive conduct, **§ 6:9**
diversification and, **§ 17:11**

LEXECON HEALTH SERVICE

Business review letter, **App. C17**

LICENSURE

“Competition and Potential Costs and Benefits of Professional Licensure,” prepared Statement of Andrew Gavil, Director, Office of Policy Planning, before Committee of Small Business, U.S. House of Representatives (Jul. 16, 2014), **App. E238**

“Death by a Thousand Haircuts: Economic Liberty and Occupational Licensure Reform,” **App. E258**

Eliminating certain occupational licensing requirements, FTC staff advocacy letter (Mar. 15, 2017), **App. D193**

“License to Compete: Occupational Licensing and the State Action Doctrine,” prepared Statement of FTC before the United States Senate Committee on the Judiciary (Feb. 2, 2016), **App. E249**

Occupational Licensing in Health Care: Sorting the Wheat from

INDEX

LICENSURE—Cont'd

the Chaff (June 19, 2020), **App. E273**

LINEN SYSTEMS FOR HEALTHCARE, LLC

Business review letters (Aug. 8, 2006), **App. C97**

LITIGATION

Discovery in staff-privilege antitrust, practitioner credentialing and, **§ 13:20**

FTC enforcement
generally, **§ 10:9**
see also Enforcement (this index)

LOBBYING

Physician-owned facilities, lobbying by hospitals against, **§ 18:3**

LOCAL GOVERNMENT ANTITRUST ACT

Antitrust exemptions, **§ 9:9**
Practitioner credentialing and, **§ 13:7**
Text of, **App. A6**

LOUISIANA HEALTH CARE ASSOCIATION

Advisory opinion, **App. D2**

LOUISIANA HOUSE OF REPRESENTATIVES

Letter from FTC to Hon. Timothy G. Burns concerning in-school dentistry (May 1, 2009), **App. D128**

LOUISIANA STATE BOARD OF DENTISTRY

FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D130**

LOW REIMBURSEMENT

Health plan market power, payer monopoly power and low reimbursement, **§ 21:5**

MANAGED CARE

Antitrust laws, **§ 1:7**

MARIN GENERAL HOSPITAL

Business review letters (Feb. 11, 1997), **App. C77**

MARKET-ALLOCATION AGREEMENTS

Generally, **§ 22:1**
Agency opposition to CON, **§ 22:3**
Antitrust ramifications of certificate-of-need proceedings, **§ 22:4**
Certificate-of-need
agency opposition, **§ 22:3**
antitrust ramifications of proceedings, **§ 22:4**
pros and cons, **§ 22:3**
Conclusion, **§ 22:6**
Health Planning Act and antitrust laws, **§ 22:2**
Health-planning activities and horizontal, **§ 22:5**
Under Section 1 of Sherman Act
horizontal agreements, **§ 4:4**
vertical agreements, **§ 5:3**

MARKET POWER

Health plans, generally. Health Plan Market Power (this index)
In market for tying product, exclusive contracts and, **§ 14:6**
Provider-Controlled Contracting Networks (this index)

MARKET REALITIES REPORTS

Current, FTC statement for, **App. D212**

MARKET REVIEW PROCESS

Massachusetts Chapter 343, An Act Enhancing
Key Provisions in effect 4-8-25, **App.N28**

MARKETS

Competitive effects in other, mergers and
see also Relevant Market (this index)
Summary report, FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D208**

MARKET SHARE

Calculation, mergers and, § 15:12

**MARYLAND HEALTH CARE
COALITION**

Business review letter, **App. C11**

**MARYLAND MEDICAL EYE
ASSOCIATES**

Advisory opinion, **App. D25**

**MASSACHUSETTS DEPARTMENT
OF PUBLIC HEALTH**

Clinic advertising, FTC staff letter
concerning (Sept. 27, 2007),
App. D120

**MASSACHUSETTS HOUSE OF
REPRESENTATIVES**

Nurse practitioners and nurse
anesthetists, FTC letter concern-
ing removal of supervision
requirement (Jan. 17, 2014),
App. D162

Optometrists treating glaucoma
patients, FTC and DOJ
Advocacy letter concerning
(Feb. 18, 2016), **App. D182**

**MAYO MEDICAL
LABORATORIES**

Advisory opinions (July 17, 1996),
App. D63

MCCARRAN-FERGUSON ACT

Health plan market power. Health
Plan Market Power (this index)
Text of, **App. A7**

MCSWEENEY, TERRELL

“Reflections on an Active Year in
Merger Enforcement,” keynote
remarks of Commissioner
McSweeney (Feb. 5, 2016),
App. E250

**MEDICAL GROUP
MANAGEMENT
ASSOCIATION**

Advisory opinion, **App. D103**

**MEDICAL SCHOOL
COLLABORATION
AGREEMENTS**

FTC Staff Advocacy letter to Ala-
bama State Senate concerning

MEDICAL SCHOOL

COLLABORATION

AGREEMENTS—Cont’d

antitrust exemption for public
university medical school agree-
ments (May. 2, 2016), **App.
D186**

**MEDICAL SOCIETY OF THE
COUNTY OF ERIE**

Advisory opinion, **App. D6**

**MEDICARE PRESCRIPTION
DRUG, IMPROVEMENT, AND
MODERNIZATION ACT**

Physician-owned facilities, § 18:2

**MEDICARE PRESCRIPTION
DRUG BENEFIT PROGRAM**

FTC Staff Advocacy Letter to
Centers for Medicare and
Medicaid Services concerning
any-willing-provider changes
(Mar. 7, 2014), **App. D164**

**MEDICARE SHARED SAVINGS
PROGRAM**

Provider-controlled contracting
networks, § 20:15

MEDSOUTH, INC.

Advisory opinion (Feb. 19, 2002),
App. D94

FTC staff follow-up letter (June 18,
2007) to 2002 staff advisory
opinion, **App. D118**

MEMBERSHIP RESTRICTIONS

Ethical issue in, § 24:8

**MEMORANDUM OF
AGREEMENT**

FTC and Antitrust Division of the
U.S. Dept. of Justice, Memoran-
dum of Agreement concerning
clearance procedures for
investigations, **App. B7**

**MENTOR GROUP FORUM FOR
EU-US LEGAL-ECONOMIC
AFFAIRS**

“Protecting Consumer Welfare in the
U.S. Health Care Sector,”
Berlin, Germany (Sept 13,

INDEX

MENTOR GROUP FORUM FOR EU-US LEGAL-ECONOMIC AFFAIRS—Cont'd 2013), **App. E221**

MERGER GUIDELINES DOJ and FTC 2023, **App. B20**

MERGERS

Generally, § 15:1, **App. B et seq.**
Affordable Care Act, § 15:22
Analyzing hospital
generally, § 15:9
Affordable Care Act, § 15:22
competitor identification and market share calculation, § 15:12
coordinating effects, § 15:15
failing company defense, § 15:20
nonprofit status, § 15:28
order, special report, physician group and healthcare facility mergers, **App. B10**
party and consultant statements and documents about purpose and effect, § 15:26
public and private commitments restraining exercise market power, § 15:27
purchasers, below
rebutting the prima facie case, below
relevant geographic market, § 15:11
relevant product market, § 15:10
Anthem, Inc.'s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E128**
As anticompetitive conduct under Section 2 of Sherman Act, § 6:11
Aviv Nevo, Deputy Assistant Attorney General for Economics, Antitrust Division, "Mergers that Increase Bargaining Leverage," Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E227**

MERGERS—Cont'd

Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010), **App. E180**
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**
Clayton Act Section 7A, premerger notification form and instructions under amended, **App. B3**
Competitors, complaints and opinions, § 15:25
Consent order provisions, FTC frequently asked questions, § 15:36
Cross-market, § 15:29
Deborah L. Feinstein, Director, Bureau of Competition, FTC, "The Forward-Looking Nature of Merger Analysis," text of remarks (Feb. 6, 2014), **App. E230**
Defenses, failing company, § 15:20
Department of Justice business review procedure, **App. B4**
"Efficiencies in Defense of Mergers: Eighteen Months After" (speech), **App. E87**
Exemption of state-action, preliminary issues, § 15:6
FTC
advisory opinions procedure, **App. B5**
Caremark Rx/AdvancePCS merger, FTC statement in closing investigation of (Feb. 11, 2004), **App. E127**
deborah L. Feinstein, Director, Bureau of Competition, FTC, "The Forward-Looking Nature of Merger Analysis," text of remarks (Feb. 6, 2014), **App. E230**
frequently asked questions, merger consent order provisions, § 15:36
guidelines on, Department of Justice and FTC, § 15:9

MERGERS—Cont'd

FTC—Cont'd

“Retrospectives at the FTC:

Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**

staff letter to Louisiana attorney general concerning Tenet Healthcare Corporation’s proposed acquisition of Slidell Memorial Hospital (Apr. 1, 2003), **App. D101**

statement in closing investigation of Caremark Rx/AdvancePCS merger (Feb. 11, 2004), **App. E127**

Statement of Richard A. Feinstein, FTC Bureau of Competition Director on the FTC’s Closure of its Investigation of Consummated hospital merger in Temple, Texas (Dec. 23, 2009), **App. E175**

statement of the Federal Trade Commission’s Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**

Guidelines on, Department of Justice and FTC, § 15:9, **App. B1**

“Health Care Mergers: Will We Get Efficiencies Claims Right?” (speech), **App. E79**

Health-plan mergers, § 15:33

Horizontal Mergers (this index)

Hospital acquisition of physician practices, § 15:32

Investigations

FTC statement in closing investigation of Caremark Rx/AdvancePCS merger (Feb. 11, 2004), **App. E127**

Statement of Richard A. Feinstein, FTC Bureau of Competition Director on the FTC’s Closure of its Investigation of

MERGERS—Cont'd

Investigations—Cont'd

Consummated hospital merger in Temple, Texas (Dec. 23, 2009), **App. E175**

Jeffrey Schmidt, Director, Bureau of Competition, prepared slides before ABA Section of Antitrust Law 2007 Fall Forum concerning “Critical Loss Analysis: A Merger Lawyer’s View” (Nov. 16, 2007), **App. E157**

“Litigating Merger Challenges: Lessons Learned,” prepared remarks by J. Thomas Rosch before Bates White Fifth Annual Antitrust Conference (June 2, 2008), **App. E165**

1984 Justice Department guidelines on, **App. B6**

Other hospital health-care sector generally, § 15:31

health-plan mergers, § 15:33

hospital acquisition of physician practices, § 15:32

other industries, § 15:34

physician practices, § 15:32

Physician practices, § 15:32

Planning for a hospital, § 15:30

Preliminary issues

generally, § 15:2

economic effects of mergers, § 15:2

interstate commerce, § 15:7

premerger notification, investigation, and preliminary relief, § 15:8

relevant federal antitrust statutes, § 15:3

Section 7 and acquisitions by non-profit entities, § 15:5

state-action exemption, § 15:6

virtual mergers and single entity status, § 15:4

Protocol for coordination in merger investigations between federal enforcement agencies and state attorneys general, **App. B3G**

Purchasers

complaints, § 15:24

INDEX

MERGERS—Cont'd

- Purchasers—Cont'd
 - opinions of, § 15:24
 - size and sophistication of, § 15:23
- Rebutting the prima facie case
 - generally, § 15:16
 - efficiencies, § 15:18
 - “failing firm,” § 15:19
 - low entry barriers, § 15:17
 - weakened competitor, § 15:19
- “Reflections on an Active Year in Merger Enforcement,” keynote remarks of Commissioner Terrell McSweeney at Antitrust Law Leaders Forum (Feb. 5, 2016), **App. E250**
- Requests for additional information, FTC appeal procedure, **App. B8**
- “Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks of Edith Ramirez before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**
- Section 7. Clayton Act (this index)
- Statement of the Federal Trade Commission’s Bureau of Competition on Guidelines for Merger Investigations (Dec. 11, 2002), **App. B3F**
- State notification laws, § 15:35
- Under Section 7 of Clayton Act
 - and acquisitions by nonprofit entities, § 15:5
 - conglomerate mergers and, § 8:15
 - premerger notification requirements, § 8:17
 - vertical mergers, § 8:14
- Under Section 1 of Sherman Act:
 - horizontal agreements, § 4:8
- Unilateral effects
 - generally, § 15:14
 - potential harms, coordinated effects, § 15:13
- United Health Group’s acquisition of Oxford Health Plans, Antitrust Division background of closing investigation of (Jul. 20, 2004), **App. E129**

MERGERS—Cont'd

- Vertical, § 15:29
 - Virtual mergers and single entity status, § 15:4
 - Voluntary self-disclosures
 - New Safe Harbor Policy, Deputy Attorney General Lisa O. Monaco, **App. B23**
- ### **MESA COUNTY PHYSICIAN INDEPENDENT PRACTICE ASSOCIATION**
- Federal Trade Commission Bureau of Competition staff advisory opinion regarding collective agreement, **App. D78A**
- ### **MESENTER ARRANGEMENTS**
- Provider-controlled contracting networks, § 20:14
- ### **MICHIGAN**
- Merger proposed, Blue Cross of Michigan and Physicians Health Plan of Mid-Michigan (Mar. 8, 2010), **App. E180**
- ### **MICHIGAN CERTIFICATE OF NEED COMMISSION**
- Letter from Joseph Miller, Assistant Chief, Antitrust Division, to Sen. Michael D. Bishop, Michigan Senate Majority Leader, concerning proposed standards (June 6, 2008), **App. C100**
- ### **MIDWEST BEHAVIORAL HEALTH LLC**
- Business review letter (Feb. 4, 2000), **App. C90**
- ### **MINNESOTA HOUSE OF REPRESENTATIVES**
- Letter from FTC concerning rural health care cooperative joint negotiations (Mar 18, 2009), **App. D125**
- ### **MOBILE AND PORTABLE DENTISTRY**
- FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to

**MOBILE AND PORTABLE
DENTISTRY—Cont'd**

Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D130**

**MOBILE HEALTH RESOURCES,
LLC**

Advisory opinions (Jan. 23, 1997), **App. D69**

MONOPOLIZATION

Generally, § 6:1

Anticompetitive conduct

generally, § 6:4

denial of access to essential facility, § 6:8

leveraging, § 6:9

mergers, § 6:11

monopoly pricing, § 6:5

other predatory or unreasonably exclusionary conduct, § 6:12

predatory pricing, § 6:12

refusals to deal, § 6:7

vertical integration, § 6:10

Attempted Monopolization (this index)

Conspiracy to monopolize, § 6:16

Health Plan Market Power (this index)

Monopoly power, § 6:3

Practitioner credentialing, analysis under Section 2 of Sherman Act, § 13:18

Shared monopoly, § 6:17

“U.S. v. AzHAA: When Does a Group Purchasing Organization Become an Illegal Monopsonist?,” prepared remarks before AHLA annual meeting (June 26, 2007), **App. E151**

**MONOPSONY AND THE
MEANING OF CONSUMER
WELFARE**

2006 Milton Handler Annual Antitrust Review, closer look at Weyerhaeuser (Dec. 7, 2006), **App. E144**

**MONTANA DEACONESS
MEDICAL CENTER**

Advisory opinions (June 28, 1996), **App. D65**

MORROS & ASSOCIATES

Business review letter, **App. C6**

**MOST-FAVORED-NATIONS
PROVISIONS**

Health plan market power, payer monopoly power and most-favored-nations provisions, § 21:6

**“NAKED” PRICE-FIXING
AGREEMENTS**

Generally, § 19:3

**NATIONAL CAPITAL SOCIETY
OF PLASTIC AND
RECONSTRUCTIVE
SURGEONS**

Advisory opinions (Apr. 23, 1991), **App. D30**

**NATIONAL CARDIOVASCULAR
NETWORK, INC.**

Business review letter, **App. C32**

NEKRITZ, ELAINE

FTC letter to Illinois State Representative Nekritz concerning proposed regulation of retail health care facilities (May. 29, 2008), **App. D124**

NETWORKS

Anthem, Inc.’s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E128**

“Antitrust Analysis of Hospital Networks and Shared Services Arrangements” (speech), **App. E65**

“Antitrust Issues Raised by Rural Health Care Networks” (speech), **App. E80**

“Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks”

INDEX

NETWORKS—Cont'd

- (speech), **App. E54**
- Dermatologists, business review letters to Dr. Oswald L. Mikell regarding proposed network of, **App. C56**
- Georgia Preferred Podiatric Medical Network, business review letters (Nov. 3, 1995), **App. C58**
- Health plan market power and exclusions from networks. Provider-Controlled Contracting Networks (this index)
- Hospice Network of New Jersey, Inc., business review letters (April 24, 1996), **App. C67**
- National Cardiovascular Network, Inc., business review letter, **App. C32**
- Oakland Physician Network, advisory opinions, **App. D50**
- Ohio Ambulance Network, Inc., advisory opinions (Jan. 23, 1997), **App. D68**
- Oklahoma Physicians Network-IPA, Inc., business review letters (Jan. 17, 1996), **App. C61**
- Orange Pharmacy Equitable Network, advisory opinions (May 19, 1999), **App. D86**
- Pharmaceutical Care Network, business review letter, **App. C18**
- Phoenix Medical Network, Inc., advisory opinions (May 19, 1998), **App. D82**
- Preferred Laboratory Access Network, business review letters (Dec. 7, 1995), **App. C60**
- Preferred Podiatric Network Inc., business review letter, **App. C45**
- Price-Fixing Agreements (this index)
- Provider-Controlled Contracting Networks (this index)
- RWHC Network, Inc., business review letters (Nov. 12, 1996), **App. C76**
- Southern Arizona Therapy Network, Inc., advisory opinions (Dec. 7, 1995), **App. D60**

NEVO, AVIV

- “Mergers that Increase Bargaining Leverage,” before Stanford Institute for Economic Policy Research and Cornerstone Research Conference on Highly Innovated Industries (Jan. 22, 2014), **App. E227**

NEW HEALTH CARE INDUSTRY CONFERENCE

- Integration, Consolidation, Competition in the Wake of the Affordable Care Act, text of remarks of Bill Baer, Assistant Attorney General, before the New Health Care Industry Conference (Nov. 15, 2015), **App. E248**

NEW JERSEY GENERAL ASSEMBLY

- Pharmacy benefit managers, letter from Federal Trade Commission Bureau of Competition and Bureau of Economics concerning regulation (Apr. 17, 2007), **App. D117**

NEW JERSEY HOSPITAL ASSOCIATION

- Business review letter, **App. C32**

NEW JERSEY PHARMACISTS ASSOCIATION

- Advisory opinions (Aug. 12, 1997), **App. D78**

NEW SAFE HARBOR POLICY

- Voluntary self-disclosures, Deputy Attorney General Lisa O. Monaco, **App. B23**

NEW YORK DEPARTMENT OF PUBLIC HEALTH

- Certificates of Public Advantage, FTC staff advocacy letter concerning (Apr. 22, 2015), **App. D170**

NEW YORK SENATE

- Letter from FTC concerning pharmacy-benefit-manager

NEW YORK SENATE—Cont’d
regulation (Mar 31, 2009), **App. D126**

NOERR-PENNINGTON DOCTRINE

Physician-owned facilities, § **18:3**

NON-COMPETE AGREEMENTS
Employee, ethical restraints, **18:4**

NONPROFIT ENTITIES
Section 7 of Clayton Act and acquisitions by, § **15:5**

NONPROFIT HEALTH CARE PROVIDERS
Ramifications of preferential pricing of
generally, § **23:4**
see also Resales of Preferentially Priced Commodities (this index)
Federal Trade Commission advisory opinions, § **23:5**

NON-PROFIT INSTITUTIONS ACT
Federal Trade Commission (FTC), opinion concerning, **App. D155, App. D156**
FTC Staff Advisory Opinions
resales of preferentially priced commodities, § **23:5**
to Kaiser Foundation Health Plan, advisory opinion on purchase of discounted pharmaceuticals under Nonprofit Institutions Act exemption (Feb. 13, 2008), **App. D122**
to Quest Analytics Group concerning Non-Profit Institutions Act (Mar. 7, 2014), **App. D165**
Overview of, § **23:3**
Resales of Preferentially Priced Commodities (this index)
Text of, **App. A4**

NONPROFIT STATUS
Mergers and, § **15:28**

NORTH CAROLINA CHIROPRACTIC ASSOCIATION
Advisory opinion, **App. D5**

NORTH CAROLINA DENTAL DECISION

“Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to Rein in State Action Immunity,” Maureen K. Ohlhausen, Commissioner (Mar 31, 2015), **App. E240**

NORTH CAROLINA SENATE BILL 743

Give state action defense to UNC healths collaborative activities, FTC staff comment, **App. D210**

NORTH MISSISSIPPI HEALTH SERVICES

Advisory opinions
(Oct. 3, 1996), **App. D71**
(Jan. 7, 1998), **App. D81**
Business review letter, **App. C22**
FTC staff advisory opinion to (Aug. 16, 2005), **App. D112**

NORTH OTTAWA COMMUNITY HOSPITAL

Advisory opinions (Oct. 22, 1996), **App. D73**

NORTH TEXAS CHAPTER, AMERICAN COLLEGE OF SURGEONS

Advisory opinion, **App. D18**

NOTIFICATION

Premerger
merger and, § **15:8**
requirements under Section 7 of Clayton Act, § **8:17**
Section 7A of Clayton Act, premerger notification form and instructions under amended, **App. B3**
statement of Commissioner Christine S. Wilson in the matter of HSR Premerger Notification, **App. E285**
State merger notification laws, § **15:35**
Washington AG guidance on healthcare transactions notifica-

INDEX

NOTIFICATION—Cont’d
tion requirement, **App. B14**

NSM PURCHASING ASSOCIATION
Business review letters (Jan. 13, 1999), **App. C88**

NURSES AND NURSING
Advanced Practice Nursing (this index)

OHIO AMBULANCE NETWORK, INC.
Advisory opinions (Jan. 23, 1997), **App. D68**

OHIO EXECUTIVE ORDER 2007-23S
FTC staff letter to Hon. William J. Seitz, Ohio State Senator, concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**

OHIO HOSPITAL PURCHASING CONSORTIUM
Business review letter, **App. C13**

OHLHAUSEN, MAUREEN K.
“An Ounce of Antitrust Prevention is Worth a Pound of Consumer Welfare: The Importance of Competition Advocacy and Premerger Notification,” before Eleventh Annual Competition Day, Santiago, Chile (Nov. 5, 2013), **App. E225**
“Brother, May I? The Challenge of Competitor Control over Market Entry” remarks before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E243**
“Protecting Consumer Welfare in the U.S. Health Care Sector,” before the Mentor Group Forum for EU-US Legal-Economic Affairs, Berlin, Germany (Sept 13, 2013), **App. E221**
“Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to

OHLHAUSEN, MAUREEN K. —Cont’d
Rein in State Action Immunity” (Mar 31, 2015), **App. E240**
“Section 5: Principles of Navigation,” before U.S. Chamber of Commerce, Washington, DC (July 25, 2013), **App. E220**
“When Regulation Protects Privilege Instead of People: Government Restraints of Trade-A Competition Enforcer’s Perspective,” text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E245**

OKLAHOMA PHYSICIANS NETWORK-IPA, INC.
Business review letters (Jan. 17, 1996), **App. C61**

OLYMPUS AMERICA, IND.
Business review letters (Aug. 29, 2001), **App. C92**

OPTOMETRY AND OPTOMETRIC CARE
Business review letter, **App. D109**
FTC and DOJ Advocacy letter to Massachusetts House of Representatives concerning permitting optometrists to treat glaucoma patients (Feb. 18, 2016), **App. D182**
FTC and DOJ joint comments to Puerto Rico House of Representatives (May 18, 2016), **App. D187**
FTC staff letter to Tennessee senate concerning bill regulating optometry (Apr. 29, 2003), **App. D102**

ORAL SURGEONS
Dentists and Oral Surgeons (this index)

ORANGE BOOK
FDA listing, **26:1**

**ORANGE LOS ANGELES
MEDICAL GROUP, INC.**

Business review letters (March 8, 1996), **App. C64**

**ORANGE PHARMACY
EQUITABLE NETWORK**

Advisory opinions (May 19, 1999), **App. D86**

ORGANIZATION

And authority, FTC, enforcement, **§ 10:7**
Antitrust Division, enforcement, **§ 10:2**

**ORTHOPEDIC ASSOCIATES OF
MOBILE, PA**

Business review letters (Apr. 16, 1997), **App. C79**

**OVERSIGHT OF THE
ENFORCEMENT OF THE
ANTITRUST LAWS**

Prepared statement of FTC, United States Senate Committee on the Judiciary Subcommittee on Antitrust, **App. E287**

OXFORD HEALTH PLANS

Antitrust Division background of closing investigation of acquisition of Oxford Health Plans (Jul. 20, 2004), **App. E129**

**PACIFIC INTERNATIONAL
HEALTH**

Advisory opinion, **App. D23**

**PAN AMERICAN MANAGEMENT
ASSOCIATES**

Advisory opinion, **App. D27**

**PARTIAL INTEGRATION OF
BUSINESS FUNCTIONS**

Joint Ventures (this index)

PARTICIPATION AGREEMENTS

Health plan market power, participation agreements between providers and payers, **§ 21:3**

PARTICIPATION PERCENTAGES

Provider-controlled contracting networks, physician network joint ventures (Statement 8), **§ 20:6**

PARTIES LIABLE

In damage actions, **§ 11:13**

**PASSAIC COUNTY MEDICAL
SOCIETY**

Advisory opinion, **App. D19**

PATENTS

“Anticompetitive Pay-for-Delay Settlements in the Pharmaceutical Industry; Why Consumers and the Federal Government are Paying Too Much for Prescription Drugs,” prepared statement of FTC before Subcommittee on Courts and Competition Policy, Committee of the Judiciary, U.S. Senate (June 3, 2009)—Richard A. Feinstein, Director, Bureau of Competition, **App. E169**

“Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” prepared remarks before second annual in-house counsel’s forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E141**

“FTC v. Actavis and the Future of Reverse Payment Cases,” remarks of Joshua D. Wright, Commissioner, FTC, before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**

“How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs,” prepared statement before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009), **App. E168**

PAYER MONOPOLY POWER

Health Plan Market Power (this index)

INDEX

PAYER-PROVIDER RELATIONSHIP

Provider-Payer Relationship (this index)

PAY-FOR-DELAY SETTLEMENTS

Exclusion Payment Settlements (this index)

PBM RELATED ADVOCACY

FTC statement for, **App. D212**

PEER REVIEW

Practitioner credentialing based on.
Practitioner Credentialing (this index)

PEER REVIEW ORGANIZATIONS OF OHIO FOUNDATION

Advisory opinion, **App. D10**

PERMANENT INJUNCTION

In Federal Trade Commission,
plaintiff, v. Surescripts, LLC
stipulated order, **App. N7**

PER SE RULE

“Virtual Mergers of Hospitals: When
Does the Per Se Rule Apply?”
(speech), **App. E83**

PETITION

FTC v. Louisiana Childrens Medical
Center, **App. N6**

PHARMACEUTICAL CARE NETWORK

Business review letter, **App. C18**

PHARMACEUTICAL INDUSTRY

“Anticompetitive Pay-for-Delay
Settlements in the Pharmaceuti-
cal Industry; Why Consumers
and the Federal Government are
Paying Too Much for Prescrip-
tion Drugs,” prepared statement
of FTC before Subcommittee on
Courts and Competition Policy,
Committee of the Judiciary, U.S.
Senate (June 3, 2009)—Richard
A. Feinstein, Director, Bureau of
Competition, **App. E169**

“Antitrust Analysis of Reverse Pay-
ments After Actavis: Three

PHARMACEUTICAL INDUSTRY

—Cont’d

Questions and Proposed
Answers,” text of remarks of
Joshua D. Wright, Commis-
sioner, FTC, before the ABA
Master Course VII (Oct. 10,
2014), **App. E235**

“Exclusion Payments to Settle
Pharmaceutical Patent Cases:
They’re B-a-c-k!,” prepared
remarks before second annual
in-house counsel’s forum on
pharmaceutical antitrust (Apr.
24, 2006), **App. E141**

Federal Trade Commission Bureau of
Competition and Bureau of Eco-
nomics letter to New Jersey
General Assembly concerning
regulation of pharmacy benefit
managers (Apr. 17, 2007), **App.
D117**

Federal Trade Commission Office of
Policy Planning, letter to Vir-
ginia House of Delegates
concerning pharmacy-benefit
managers (PBM) regulation
(Oct. 2, 2006), **App. D116**

Follow-on biologics, Pay-for-Delay
Settlements, and Authorized
Generics: Thoughts on How
Competition Law Can Best
Protect Consumer Welfare in the
Pharmaceutical Context, J.
Thomas Rosch, Commissioner,
FTC (Nov. 19, 2009), **App.
E174**

FTC amicus brief, Jazz
Pharmaceuticals v. Avadel CNS
Pharmaceuticals, **App. D207**

FTC staff advisory opinion to Kaiser
Foundation Health Plan on
purchase of discounted
pharmaceuticals under Nonprofit
Institutions Act exemption (Feb.
13, 2008), **App. D122**

“FTC v. Actavis and the Future of
Reverse Payment Cases,”
remarks of Joshua D. Wright,
Commissioner, FTC, before the
Concurrences Journal Annual

PHARMACEUTICAL INDUSTRY

—Cont’d

- Dinner, New York, New York (Sept. 26, 2013), **App. E224**
- House Bill 971 (Community Pharmacy Fairness Act of 2007), Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee (Oct. 18, 2007)—David Wales, Bureau of Competition, **App. E156**
- House Bill 1332 (“HB 1332” or the “Bill”) that would regulate the contractual relationships between pharmacy-benefit managers (“PBMs”) and “covered entities,” **App. D108**
- Keynote remarks of Commissioner Rebecca Kelly Slaughter, FTC/DOJ Pharmaceutical task force workshop, **App. E286**
- Letter from FTC to New York Senator concerning pharmacy-benefit manager regulation (Mar 31, 2009), **App. D126**
- Letter from Markus H. Meier, Crouse Health Hospital, sale of discount pharmaceuticals to employees and retirees, **App. D200**
- Overview of FTC actions in pharmaceutical products and distribution (December 2025), **App. L2**
- Patent settlements and Supreme Court, FTC prepared remarks, **App. E209**
- Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context, J. Thomas Rosch, Commissioner, FTC (Nov. 19, 2009), **App. E174**
- “Pay-for-Delay Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers’ Wallets, and Help Pay for

PHARMACEUTICAL INDUSTRY

—Cont’d

- Health Care Reform (The § 35 Billion Solution)” prepared remarks of Jon Leibowitz (June 23, 2009), **App. E171**
- Post-patent pharmaceutical markets, issues in, **App. E260**
- Prepared Statement of FTC and Pharmaceutical Industry before Committee of Judiciary, US Senate (June 17, 2003)—Timothy J. Muris, Chairman, FTC, **App. E121**
- Prepared Statement of FTC before Subcommittee on Commerce, Trade, and Consumer Protection, Committee on Energy and Commerce, US House of Representatives (Mar. 31, 2009)—J. Thomas Rosch, Commissioner, FTC, **App. E168**
- Staff advisory opinion letter, Markus Meier to Doylestown Health, discounted pharmaceuticals and devices, Non-Profit Institutions Act, **App. D204**
- Staff letter to Rep. Patrick McHenry concerning proposed bill regulating pharmacy benefit manager contractual relationships (Jul. 15, 2005), **App. D111**
- Statement of Timothy J. Muris, Chairman, FTC before the Committee on Energy and Commerce, **App. E112**
- Study on pharmacy benefit managers, **App. E280**

**PHARMACEUTICAL
MANUFACTURERS
ASSOCIATION**

- Business review letter, **App. C33**

PHARMACEUTICAL MERGERS

- FTC-DOJ workshop summary, **App. N4**

INDEX

PHARMACEUTICAL PATENT DISPUTES

- Settlement of disputes, antitrust
issues (speech by Thomas B.
Leary)
(Part I), **App. E102**
(Part II), **App. E103**

PHARMACEUTICAL TASK FORCE WORKSHOP, FTC/ DOJ

- Keynote remarks of Commissioner
Rebecca Kelly Slaughter, **App.**
E286

PHOENIX MEDICAL NETWORK, INC.

- Advisory opinions (May 19, 1998),
App. D82

PHYSICIAN-OWNED FACILITIES

- Generally, § 18:1 et seq.
- Actions to combat competition from
medical staff members, § 18:3
- Adverse selection, § 18:2
- Ambulatory surgery centers (ASCs),
§ 18:2 et seq.
- Anticompetitive actions taken by
hospitals, generally, § 18:2
- Antitrust principles, application of,
§ 18:5
- Application of antitrust principles,
§ 18:5
- Boycotting by hospital, § 18:3
- Case summaries, § 18:5
- Certificate of need (CON), hospital's
opposition, § 18:3
- Community and payer moral suasion,
§ 18:3
- Competition between hospitals and.
See entries throughout this topic
- Conflicts of interest, § 18:2, § 18:3
- "Cost-shifting," § 18:2
- "Cross-subsidization," § 18:2
- Economic credentialing, § 18:3
- Economic interest. See entries
throughout this topic
- Employee non-compete agreements,
ethical restraints, § 18:4

PHYSICIAN-OWNED FACILITIES —Cont'd

- Establishment of competing facility
by hospital, § 18:3
- Ethical restraints, employee non-
compete agreements, § 18:4
- Exclusive contracting policies, § 18:3
- "Free-riding," § 18:2
- Hospitals and, competition between.
See entries throughout this topic
- Investment interest. See entries
throughout this topic
- Issue background, § 18:2
- Joint ventures, § 18:3
- Lobbying by hospitals against, § 18:3
- Medical staff members, actions to
combat competition from,
§ 18:3
- Medicare Prescription Drug,
Improvement, and Moderniza-
tion Act, § 18:2
- Noerr-Pennington doctrine, § 18:3
- Non-compete agreements of
employee, ethical restraints,
§ 18:4
- Referrals, § 18:2
- Selective contracting policies, § 18:3
- Single-specialty hospitals (SSHs),
§ 18:2 et seq.
- Stark anti-referral laws, § 18:2
- Unfair competition, § 18:2

PHYSICIANS

- See also Practitioner Credentialing
(this index)
- Alaska House of Representatives,
physician joint negotiation stat-
ute (Jan. 18, 2002), **App. D92**
- Collective bargaining legislative
exemption, letter from FTC to
Insurance Committee, Ohio
House of Representatives
(October 16, 2002), **App. D95**
- Exclusive contracts between hospitals
and. Exclusive Contracts (this
index)
- Hospital acquisition of physician
practices, § 15:32
- Joint negotiation statute
Alaska House of Representatives,
physician joint negotiation

PHYSICIANS—Cont'd

- Joint negotiation statute—Cont'd statute, **App. D92**
- Washington State House of Representatives, physician joint negotiation statute, **App. D93**
- Joint ventures
 - between hospitals and physicians, analysis, § **16:10**
- Provider-Controlled Contracting Networks (this index)
- Mergers of practices of, § **15:32**
- Network joint ventures. Provider-Controlled Contracting Networks (this index)
- Washington State House of Representatives, physician joint negotiation statute (Feb. 8, 2002), **App. D93**

PLANNING

- See also Health Planning; Health Planning Act; Health Plans (this index)
- For mergers
 - See also Health Planning; Health Planning Act; Health Plans (this index)
- hospitals, § **15:30**

PLASTIC SURGERY ASSOCIATES OF CONNECTICUT, LLC

- Business review letters (June 28, 1996), **App. C68**

“POACHING”

- Limitations on, ethical restraints, § **24:5**

PORTABLE AND MOBILE DENTISTRY

- FTC Staff comments to Louisiana State Board of Dentistry regarding proposed modifications to Louisiana Rules regarding the practice of portable and mobile dentistry (Dec. 9, 2009), **App. D130**

PRACTICE FORM

- Restraints on, ethical issue, § **24:7**

PRACTICE STANDARDS

- Relating to quality, ethical issue, § **24:9**

PRACTITIONER CREDENTIALING

- Generally, § **13:1**
- Allied health practitioners, § **13:19**
- Analysis under Section 1 of Sherman Act
 - generally, § **13:10**
 - capacity to conspire, § **13:11**
 - conspiracy in fact, § **13:12**
 - standard of analysis, § **13:13**
- Analysis under Section 2 of Sherman Act, § **13:18**
- Analysis under Section 1 of Sherman Act: analysis under rule of reason
 - generally, § **13:14**
 - effect on competition, § **13:16**
 - intent and purpose, § **13:17**
 - relevant market, § **13:15**
- Antitrust standing to challenge adverse decision, § **13:9**
- Discovery in staff-privilege antitrust litigation, § **13:20**
- Health Care Quality Improvement Act, § **9:12**, § **13:8**
- Hospital organization and the process of, § **13:2**
- Legal theories and parties, § **13:3**
- Minimizing antitrust risks, § **13:21**
- Preliminary issues
 - generally, § **13:4**
- Health Care Quality Improvement Act, § **13:8**
- interstate commerce, § **13:5**
- Local Government Antitrust Act, § **13:7**
- state-action exemption, § **13:6**

PREDATORY CONDUCT

- Section 2 of Sherman Act, diversification and see also Anticompetitive Conduct (this index)
- refusals to deal, § **17:9**
- steering as predatory conduct, § **17:12**

INDEX

PREDATORY PRICING

Under Section 2 of Sherman Act,
§ 6:6

PREFERRED LABORATORY ACCESS NETWORK

Business review letters (Dec. 7,
1995), **App. C60**

PREFERRED PHYSICIANS MEDICAL GROUP

Business review letters (July 23,
1999), **App. C89**

PREFERRED PODIATRIC NETWORK INC.

Business review letter, **App. C45**

PRELIMINARY INJUNCTION

Pursuant to Section 13(b) of the
Federal Trade Commission Act,
App. N2

PREMERGER NOTIFICATION

“An Ounce of Antitrust Prevention is
Worth a Pound of Consumer
Welfare: The Importance of
Competition Advocacy and
Premerger Notification,” before
Eleventh Annual Competition
Day, Santiago, Chile (Nov. 5,
2013), **App. E225**

Mergers and, § 15:8

Requirements under Section 7 of
Clayton Act, § 8:17

Section 7A of Clayton Act, premerger
notification form and instruc-
tions under amended, **App. B3**

Statement of Commissioner Christine
S. Wilson in the matter of HSR
Premerger Notification, **App.
E285**

PRESCRIPTION DRUGS

FTC Staff Advocacy Letter to
Centers for Medicare and
Medicaid Services concerning
any-willing-provider changes to
Medicare prescription drug ben-
efit program (Mar. 7, 2014),
App. D164

PRESENTATION HEALTH SYSTEM

Advisory opinion, **App. D41**

PRICE DISCRIMINATION

Generally, § 7:1

As vertical agreement under Section
1 of Sherman Act, § 5:9

PRICE EXCHANGES

Price-Fixing Agreements (this index)

PRICE-FIXING AGREEMENTS AND PRICE AND WAGE EXCHANGES

Generally, § 19:1 *et seq.*

Ancillary price-fixing agreements,
§ 20:8

Contracting networks. Provider-Con-
trolled Contracting Networks
(this index)

Ethical restraints on, § 24:3

Exchanging or disseminating pricing
information, competitor agree-
ments to, § 19:6

Exclusive contracts and vertical,
§ 14:15

Forms of provider price-fixing agree-
ments, § 19:4

Horizontal, under Section 1 of Sher-
man Act, § 4:2

Joint ventures. Provider-Controlled
Contracting Networks (this
index)

“Naked” price-fixing agreements,
§ 19:3

Negotiations among providers with
payers, concerted, § 19:5

Networks. Provider-Controlled
Contracting Networks (this
index)

Physician network joint ventures
(Statement 8). Provider-Con-
trolled Contracting Networks
(this index)

Price exchanges. See entries
throughout this topic

Provider-Controlled Networks (this
index)

**PRICE-FIXING AGREEMENTS
AND PRICE AND WAGE
EXCHANGES—Cont'd**

Statement 8. Provider-Controlled
Contracting Networks (this
index)

Statement 9. Provider-Controlled
Contracting Networks (this
index)

Vertical Price-Fixing Agreements
(this index)

PRICING

Monopoly, under Section 2 of Sher-
man Act, § **6:5**

Predatory, under Section 2 of Sher-
man Act, § **6:6**

**PRIMARY AND EXCLUSIVE
JURISDICTION**

Generally, § **9:6**

**PRIMARY AND SPECIALIST
MEDICAL CENTER, LLC**

Business review letters (July 2,
1996), **App. C70**

PRIVATE ACTIONS

Generally, § **11:1**

Damages as element of damage
action, § **11:8**

Defenses

generally, § **11:9**

antitrust defenses in nonantitrust
cases, § **11:12**

in pari delicto and related defenses,
§ **11:11**

statute of limitations, § **11:10**

Effect of government judgments and
prior violations, § **11:14**

Elements of

generally, § **11:2**

antitrust injury, § **11:6**

business or property, § **11:4**

causation, § **10:4**, § **11:5**

damages, § **11:8**

injury, § **11:3**

standing, § **11:7**

Injunctive relief, § **11:15**

Parties liable, § **11:13**

PRIVATE ACTIONS—Cont'd

Practitioner credentialing, antitrust
standing to challenge, § **13:9**

PRIVATE HEALTHCARE SYSTEM

Advisory opinion, **App. D16**

**PRIVATE TREBLE-DAMAGE
LITIGATION**

Injury in, under Robinson-Patman
Act, § **7:11**

PRODUCTS

Separate and distinct, exclusive
contracts and, § **14:4**

Tying Arrangements (this index)

PROKLAHOMA CARE, INC.

Business review letters (Jan. 17,
1996), **App. C61**

PROPERTY

As element of damage action, § **11:4**

**PROVIDER-CONTROLLED
CONTRACTING NETWORKS**

Generally, § **20:1 et seq.**

Accountable care organizations,
Federal Trade Commission and
Department of Justice Statement
of Antitrust Enforcement Policy,
§ **20:15**

Ancillary price-fixing agreements and
clinical integration, § **20:8**

Clinical integration, ancillary price-
fixing agreements and, § **20:8**

Exclusivity in physician network
joint ventures and safety zones,
Statement 8, § **20:6**

Federal Trade Commission and
Department of Justice Statement
of Antitrust Enforcement Policy,
§ **20:15**

Joint ventures. Physician network
joint ventures (Statement 8),
below

Market power

multi-provider networks, § **20:12**

physician network joint ventures
(Statement 8), § **20:9**

INDEX

PROVIDER-CONTROLLED CONTRACTING NETWORKS

—Cont'd

- Medicare Shared Savings Program,
Accountable care organizations,
§ 20:15
- Messenger arrangements, § 20:14
- Multi-provider networks (Statement
9)
 - generally, § 20:10 to 20:13
 - market power, § 20:12
 - price-fixing agreements, generally,
§ 20:11
 - vertical agreements, § 20:13
- Participation percentages, exclusivity,
and safety zones, Statement 8,
§ 20:6
- Physician network joint ventures
(Statement 8)
 - generally, § 20:4 to 20:9
 - ancillary price-fixing agreements
and clinical integration,
§ 20:8
 - antitrust safety zones, § 20:5,
§ 20:6
 - exclusivity in physician network
joint ventures and safety
zones, § 20:6
 - financial risk sharing and antitrust
safety zones, § 20:5
 - market power, § 20:9
 - outside antitrust safety zones,
§ 20:7, § 20:8
 - participation percentages, exclusiv-
ity, and safety zones, § 20:6
- Price-fixing agreements, generally,
§ 20:3 et seq.
- Vertical agreements, multi-provider
networks, § 20:13

PROVIDER DIVERSIFICATION

- Generally, § 17:1
- And Section 7 of Clayton Act, § 17:7
- And Section 1 of Sherman Act,
§ 17:3
- And Section 2 of Sherman Act
 - generally, § 17:8
 - steering as predatory conduct,
§ 17:12

PROVIDER DIVERSIFICATION —Cont'd

- And Section 2 of Sherman Act:
 - monopolization and attempted
monopolization
generally, § 17:8
 - diversification and leveraging,
§ 17:11
 - diversification and predatory refus-
als to deal, § 17:9
 - diversification and the essential
facilities doctrine, § 17:10
- And steering by other providers,
§ 17:14
- Diversification and reciprocal deal-
ing, § 17:6
- Diversification resulting from an
exclusive dealing agreement,
§ 17:4
- Diversification resulting in a tying
arrangement, § 17:5
- Relevant legal theories, § 17:2
- Risk minimization in hospital
diversification, § 17:13

PUERTO RICO

- Optometry, FTC and DOJ joint com-
ments to Puerto Rico House of
Representatives (May 18, 2016),
App. D187
- Treasury and Financial Affairs Com-
mittee, FTC Staff letter object-
ing to bill permitting health-care
providers to collectively negoti-
ate fees (Jan. 30, 2008), **App.**
D121

PURCHASERS

- Group purchasing programs, joint
ventures and, § 16:8
- Mergers (this index)

PURPOSE OR INTENT

- Practitioner credentialing and, under
Section 1 of Sherman Act
generally, § 13:17
- see also Anticompetitive Purpose
or Intent Element (this index)

QUALITY

- Standards of practice relating to, as
ethical issue, § 24:9

**QUALITY HEALTH-CARE
COALITION ACT**

Speeches, **App. E82, App. E89, App. E90**

QUEST ANALYTICS GROUP

FTC Staff Advisory Opinion
concerning Non-Profit Institu-
tions Act (Mar. 7, 2014), **App. D165**

“QUICK LOOK” RULE

Sherman Act Section 1 violations,
anticompetitive effect elements,
§ **3:13**

RAMIREZ, EDITH

“Retrospectives at the FTC: Promot-
ing an Antitrust Agenda,” text of
remarks before the George
Washington University Law
School Merger Transactions
Symposium (June 28, 2013),
App. E233

**REBECCA KELLY SLAUGHTER
DISSENTING STATEMENT**

Gateway Pet Memorial Services/West
Coast, **App. F10**

**RE BYSTOLIC ANTITRUST
LITIGATION**

FTC amicus brief, **App. D211**

RECIPROCAL DEALING

Diversification and, § **17:6**

**RECIPROCAL DEALING
AGREEMENTS**

As vertical agreements under Section
1 of Sherman Act, § **5:8**

REFERRALS

Physician-owned facilities, § **18:2**

REFUSAL TO DEAL

As anticompetitive conduct under
Section 2 of Sherman Act, § **6:7**
Concerted, under Section 1 of Sher-
man Act, § **4:7**
Diversification and predatory, § **17:9**

REGULATED INDUSTRIES

Federal Government (this index)

REIMBURSEMENT

Health plan market power, payer
monopoly power and low
reimbursement, § **21:5**

**RELATING TO WISCONSIN RATE
REVIEW PROGRAM**

Business review letter, **App. C4**

RELEVANT MARKETS

Generally, § **2:1 to 2:6**
Conclusion, § **2:6**
Exclusive contracts and, § **14:11**
Interstate commerce requirement,
§ **2:2**
Mergers and
geographic markets, § **15:11**
product market, § **15:10**
Under Section 7 of Clayton Act,
§ **8:4**
Under Section 1 of Sherman Act
geographic market, § **2:5**
practitioner credentialing and,
§ **13:15**
product market, § **2:4**

RELIEF

In civil cases of Antitrust Division,
§ **10:5**
Injunctive, in damage actions,
§ **11:15**
Preliminary, mergers and, § **15:8**
Under Section 7 of Clayton Act
generally, § **8:18**
Antitrust Division and Federal
Trade Commission, § **8:18**
private parties, § **8:19**

REMARKS OF BILL BAER

Integration, Consolidation, Competi-
tion in the Wake of the Afford-
able Care Act, text of remarks
before the New Health Care
Industry Conference (Nov. 15,
2015), **App. E248**

**REMARKS OF DEBORAH L.
FEINSTEIN**

“Antitrust Enforcement in Health
Care: Proscription, Not Prescrip-
tion,” text of remarks before the

INDEX

REMARKS OF DEBORAH L. FEINSTEIN—Cont'd

Fifth National Accountable Care Organization Summit (June 19, 2014), **App. E232**

“FTC v. Sysco: Old School Antitrust With Modern Economic Tools” text of remarks before GCR Live (Sept. 18, 2015), **App. E246**

“The Forward-Looking Nature of Merger Analysis,” text of remarks (Feb. 6, 2014), **App. E230**

REMARKS OF EDITH RAMIREZ

“Retrospectives at the FTC: Promoting an Antitrust Agenda,” text of remarks before the George Washington University Law School Merger Transactions Symposium (June 28, 2013), **App. E233**

“The Horizontal Merger Guidelines Five Years Later” text of remarks before Georgetown University Law Center Ninth Annual Global Antitrust Enforcement Symposium (Sept. 29, 2015), **App. E247**

REMARKS OF JON LEIBOWITZ

“Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” prepared remarks before second annual in-house counsel’s forum on pharmaceutical antitrust (Apr. 24, 2006), **App. E141**

“Pay-for-Delay Settlements in the Pharmaceutical Industry: How Congress Can Stop Anticompetitive Conduct, Protect Consumers’ Wallets, and Help Pay for Health Care Reform (The § 35 Billion Solution)” (June 23, 2009), **App. E171**

REMARKS OF JOSHUA D. WRIGHT

“Antitrust Analysis of Reverse Payments After Actavis: Three

REMARKS OF JOSHUA D. WRIGHT—Cont'd

Questions and Proposed Answers,” text of remarks before the ABA Master Course VII (Oct. 10, 2014), **App. E235**

“FTC v. Actavis and the Future of Reverse Payment Cases,” before the Concurrences Journal Annual Dinner, New York, New York (Sept. 26, 2013), **App. E224**

“Recent Antitrust Enforcement Initiatives at the U.S. Federal Trade Commission,” before the ABA Section of International Law Conference, Beijing, China (Sept. 16, 2013), **App. E222**

“The FTC’s Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets,” before the 2013 Georgetown Global Antitrust Symposium Dinner, Washington, D.C. (Sept. 24, 2013), **App. E223**

REMARKS OF J. THOMAS ROSCH

“Clinical Integration in Antitrust: Prospects for the Future,” prepared remarks before AHLA and ABA Antitrust and Health Law Section 2007 Antitrust in Health Care Seminar (Sept. 17, 2007), **App. E154**

“Enforcement Strategies in the Health Care Industry,” prepared remarks before ABA Health Law Section Sixth Annual Healthcare Summit (Nov. 17, 2008), **App. E167**

“Litigating Merger Challenges: Lessons Learned,” prepared remarks before Bates White Fifth Annual Antitrust Conference (June 2, 2008), **App. E165**

Monopsony and the meaning of consumer welfare, a closer look at Weyerhaeuser (Dec. 7, 2006), **App. E144**

Pay-for-Delay Settlements, Authorized Generics, and Follow-on

**REMARKS OF J. THOMAS ROSCH
—Cont’d**

Biologics: Thoughts on How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context (Nov. 19, 2009), **App. E174**

REMARKS OF JULIE BRILL

“A Common Goal: The U.S. Federal Trade Commission’s Healthcare Enforcement Program and its Implications for ACOs,” text of remarks by Julie Brill, Commissioner, FTC, before the Sixth Annual Accountable Care Organization Summit Preconference (June 17, 2015), **App. E244**

“What’s Past is Prologue: FTC’s Competition and Consumer Protection Priorities,” text of remarks by Julie Brill, Commissioner, FTC, before the ABA Fall Forum (Nov. 6, 2014), **App. E236**

REMARKS OF LINA M. KHAN

Study on Pharmacy Benefit Managers, **App. E280**

REMARKS OF MARK BOTTI

“Observations on and From the Antitrust Division’s buyer-side cases: How can ‘lower’ prices violate the antitrust laws” at Antitrust Law Spring Meeting (Apr. 19, 2007), **App. E147**

REMARKS OF MARTIN GAYNOR

“Efficiencies Analysis: False Dichotomies, Modeling, and Applications to Health Care,” text of remarks before the 2014 American Antitrust Institute Annual Conference, **App. E234**

**REMARKS OF MARY LOU
STEPTOE**

(Speech), **App. E40**

**REMARKS OF MAUREEN K.
OHLHAUSEN**

“Brother, May I? The Challenge of Competitor Control over Market

**REMARKS OF MAUREEN K.
OHLHAUSEN—Cont’d**

Entry” remarks before George Mason School of Law Global Antitrust Economics Conference (May 29, 2015), **App. E243**

“When Regulation Protects Privilege Instead of People: Government Restraints of Trade—A Competition Enforcer’s Perspective,” text of remarks before The Antitrust Enforcement Symposium 2015 of Journal of Antitrust Enforcement (June 27, 2015), **App. E245**

**REMARKS OF PAMELA JONES
HARBOUR**

“A ‘Check-Up’ of Selected Health Care Activity at FTC” (Mar. 30, 2005), **App. E132**

“Clinical Integration: The Changing Climate and What It Means for Care Coordination” (Apr. 27, 2009), **App. E170**

**REMARKS OF REBECCA KELLY
SLAUGHTER**

Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients, **App. E267**
Keynote, FTC/DOJ Pharmaceutical Task Force Workshop, **App. E286**

**REMARKS OF TERRELL
MCSWEENEY**

Federal Trade Commission, Commissioner, text of remarks (Apr 28, 2015), **App. E241**

“Reflections on an Active Year in Merger Enforcement,” keynote remarks (Feb. 5, 2016), **App. E250**

**REMARKS OF THOMAS B.
LEARY**

Generally, **App. E114**

**REMARKS OF TIMOTHY J.
MURIS**

Generally, **App. E113, App. E115**

INDEX

REMARKS OF WILLIAM BLUMENTHAL

“The Rhetoric of Gun Jumping,”
remarks before Association of
Corporate Counsel Annual
Antitrust Seminar of Greater
New York Chapter (Nov. 10,
2005), **App. E138**

REMARKS OF WILLIAM J. BAER

“Origin of the Species: The 100 Year
Evolution of the Clayton Act,”
text of remarks before ABA
Clayton Act 100th Anniversary
Symposium (Dec. 4, 2014),
App. E237

RESALES OF PREFERENTIALLY PRICED COMMODITIES

Generally, § 23:1

Non-Profit Institutions Act

generally, § 23:3

see also entries throughout this
topic

Practical considerations, § 23:6

Ramifications of preferential pricing
on nonprofit health care provid-
ers

Federal Trade Commission advi-
sory opinions, § 23:5

NPIA court decisions, § 23:4

Robinson-Patman Act

generally, § 23:2

see also entries throughout this
topic

RESOURCES

Antitrust laws, § 1:10

RESTRAINING ORDER

Temporary, pursuant to Section 13(b)
of the Federal Trade Commis-
sion Act, **App. N2**

RESTRAINTS

Agreements (this index)

Ethical Restraints (this index)

RETAIL HEALTH CARE FACILITIES

Letter from FTC to Illinois State
Representative concerning

RETAIL HEALTH CARE FACILITIES—Cont’d

proposed regulation of retail
health care facilities (May 29,
2008), **App. D124**

REVERSE PAYMENTS

“Antitrust Analysis of Reverse Pay-
ments After Actavis: Three
Questions and Proposed
Answers,” text of remarks of
Joshua D. Wright, Commis-
sioner, FTC, before the ABA
Master Course VII (Oct. 10,
2014), **App. E235**

“FTC v. Actavis and the Future of
Reverse Payment Cases,”
remarks of Joshua D. Wright,
Commissioner, FTC, before the
Concurrences Journal Annual
Dinner, New York, New York
(Sept. 26, 2013), **App. E224**

REVISED JURISDICTIONAL THRESHOLDS

Section 7A, Hart Scott-Rodino
premerger notification filings
Clayton Act, **App. B26**

RHODE ISLAND ATTORNEY GENERAL

FTC staff letter to Patrick C. Lynch,
Attorney General of Rhode
Island (Apr. 8, 2004), **App.
D106**

RIO GRANDE EYE ASSOCIATES, P.A.

Business review letter, **App. C91**

RISK MINIMIZATION

Exclusive contracts and, § 14:16

In hospital diversification, § 17:13

Practitioner credentialing and,
§ 13:21

RISK SHARING

Provider-controlled contracting
networks, antitrust safety zones,
§ 20:5

ROBINSON-PATMAN ACT

Generally, § 7:2

ROBINSON-PATMAN ACT

—Cont'd

Exemptions and applicability, § 7:10
Injury in private treble-damage litigation, § 7:11

Overview of, § 23:2

Resales of Preferentially Priced Commodities (this index)

Section 2(a)

competitive effects, § 7:5

defenses, § 7:6

essential elements, § 7:3

jurisdictional requirements, § 7:4

Section 2(c), § 7:7

Section 2(f), § 7:9

Sections 2(d) and 2(e), § 7:8

Text of, excerpts, **App. A3**

ROSS HOSPITAL (FEB. 11, 1997)

Business review letters, **App. C77**

RULE OF REASON

Practitioner credentialing, analysis under Sherman Antitrust Act
Section 1

generally, § 13:14

effect on competition, § 13:16

intent and purpose, § 13:17

relevant market, § 13:15

Unreasonably anticompetitive effect element, Sherman Antitrust Act
Section 1, § 3:11

**RURAL HEALTH CARE
COOPERATIVES**

Letter from FTC to Minnesota State Representative concerning joint negotiations (Mar 18, 2009),
App. D125

RWHC NETWORK, INC.

Business review letters (Nov. 12, 1996), **App. C76**

SANOFI/ MAZE THERAPEUTICS

Chair Lina M. Khan joined by commissioner Rebecca Kelly Slaughter, statement of, **App. B24**

**SANTA FE, NEW MEXICO
MANAGED CARE
ORGANIZATION, INC.**

Business review letters

(Feb. 12, 1997), **App. C78**

(Sept. 16, 1998), **App. C87**

SCHMIDT, JEFFREY

Prepared slides of Jeffrey Schmidt, Director, Bureau of Competition, before ABA Section of Antitrust Law 2007 Fall Forum concerning “Critical Loss Analysis: A Merger Lawyer’s View” (Nov. 16, 2007), **App. E157**

SECOND CIRCUIT ORDER

Pharma Bro Martin Shkreli’s lifetime ban, upholding

federal trade commission, statement of, **App. B25**

**SEESKIN, PAAS, BLACKBURN &
CO.**

Business review letter, **App. C43**

SELECTIVE CONTRACTING

Physician-owned facilities, § 18:3

SENATOR BRAD HUTTO

S.45 / H.3580 & S.669 APRNs, **App. D214**

SENATOR WILLIAM J. SEITZ

FTC staff letter concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**

SERVICE FOR YOU

Business review letter, **App. C19**

SERVICES

Conditional sale of one service, on purchase of another service, exclusive contracts and, § 14:5

Joint ventures among competitors to provide new, § 16:9

SETTLEMENTS

Exclusion Payment Settlements (this index)

INDEX

SEWARD, JAMES I.

FTC letter to New York Senator
James I. Seward concerning
pharmacy-benefit-manager
regulation (Mar 31, 2009), **App.
D126**

SHARED MONOPOLY

Generally, § 6:17

SHERMAN ANTITRUST ACT (SHERMAN ACT)

Generally, § 3:1

“Effect on commerce” test, § 2:2

Expectation of effect on commerce,
§ 2:2

“In commerce” test, § 2:2

“Infected activities,” § 2:2

Relevant geographic market, § 2:1

Section 2

generally, § 6:1

conspiracy to monopolize, § 6:16

exclusive contracts, § 14:13

mergers and, § 15:3

practitioner credentialing, § 13:18

Section 2: attempted monopolization

generally, § 6:13

dangerous probability of success,
§ 6:15

specific intent and predatory
conduct, § 6:14

Section 2: diversification and

generally, § 17:8

diversification and essential facili-
ties doctrine, § 17:10

diversification and leveraging,
§ 17:11

diversification and predatory refus-
als to deal, § 17:9

steering as predatory conduct,
§ 17:12

Section 1: diversification under

generally, § 17:3

diversification and reciprocal deal-
ing, § 17:6

diversification resulting from an
exclusive dealing agreement,
§ 17:4

diversification resulting in a tying
arrangement, § 17:5

SHERMAN ANTITRUST ACT (SHERMAN ACT)—Cont’d

Section 1: fundamental concepts,
relevant market

generally, § 2:3

relevant geographic market, § 2:5

relevant product market, § 2:4

Section 1: fundamental concepts of
generally, § 3:1

elements of Section 1 violation.

Violations of Section 1 of
Sherman Act (this index)

interstate commerce requirement,
§ 2:2

Section 1: horizontal agreements
under

generally, § 4:1

agreements to exchange or dissem-
inate information, § 4:3

bid-rigging agreements, § 4:5

concerted refusals to deal, § 4:7

covenants not to compete, § 4:6

horizontal market-allocation agree-
ments, § 4:4

horizontal price-fixing agreements,
§ 4:2

mergers and joint ventures, § 4:8

standard-setting programs, § 4:10

unfair competition and dirty tricks,
§ 4:9

Section 1: mergers, § 15:3

Section 2: monopolization

generally, § 6:2

monopoly power, § 6:3

Section 2: monopolization—

anticompetitive conduct

generally, § 6:4

denial of access to essential facil-
ity, § 6:8

leveraging, § 6:9

mergers, § 6:11

monopoly pricing, § 6:5

other predatory or unreasonably
exclusionary conduct, § 6:12

predatory pricing, § 6:6

refusals to deal, § 6:7

text of, excerpts, **App. A1**

vertical integration, § 6:10

**SHERMAN ANTITRUST ACT
(SHERMAN ACT)—Cont'd**

Section 1: practitioner credentialing—analysis under rule of reason

generally, § 13:14

effect on competition, § 13:16

intent and purpose, § 13:17

relevant market, § 13:15

Section 1: practitioner credentialing under

generally, § 13:10

capacity to conspire, § 13:11

conspiracy in fact, § 13:12

standard of analysis, § 13:13

Section 1: vertical agreements under generally, § 5:1

distributorship terminations, § 5:4

dual distribution, § 5:5

exclusive dealing agreements, § 5:7

price discrimination and commercial bribery, § 5:9

reciprocal dealing agreements, § 5:8

tying agreements, § 5:6

vertical market-allocation agreements, § 5:3

vertical price-fixing agreements, § 5:2

Subject matter jurisdiction, § 2:2

SIERRA COMMCARE, INC.

Business review letters (Aug. 15, 1996), **App. C72**

SIMONS, JOSEPH J.

“A Health Care Check on COPAs; Assessing the Impact of Certificates of Public Advantage in Health Care Markets” (June 18, 2019), **App. E268**

FDA / FTC Biosimilars Workshop (March 9, 2020), **App. E271**

SINGLE-SPECIALTY HOSPITALS (SSHS)

Physician-owned facilities, § 18:2 et seq.

SLAUGHTER, REBECCA KELLY

Adoption of the Statement of Enforcement Policy, Unfair Methods of Competition Under Section 5 of the FTC Act, **App. E288**

“Antitrust and Health Care Providers: Policies to Promote Competition and Protect Patients,” **App. E267**

Contact Lens Rule (June 22, 2020), **App. E274**

Keynote remarks, Pharmaceutical Task Force Workshop, **App. E286**

SMITH, TERENCE L., M.D.

Business review letters (Oct. 17, 1996), **App. C75**

SOLICITATION

Limitations on, ethical restraints, § 24:6

Of government action, antitrust exemption, § 9:8

SOUTH CAROLINA HOUSE OF REPRESENTATIVES

FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**

Joint statement of FTC and Antitrust Division on Certificate-of-Need laws and proposed legislation (Jan. 16, 2016), **App. D179**

SOUTH CAROLINA STATE HEALTH PLANNING COMMITTEE

U.S. Department of Justice Antitrust Division letter concerning certificate-of-need regulation (Dec. 8, 2006), **App. C99**

SOUTHEAST MANAGED CARE, INC.

Advisory opinion, **App. D46**

SOUTHERN ARIZONA THERAPY NETWORK, INC.

Advisory opinions (Dec. 7, 1995), **App. D60**

INDEX

SOUTHERN HEALTH

CORPORATION (MARCH 5, 1996)

Business review letters, **App. C63**

SOUTHWESTERN MICHIGAN HEALTH SYSTEMS AGENCY

Business review letter, **App. C12**

SOUTHWEST FLORIDA ORAL SURGERY ASSOCIATES

Advisory opinions (Dec. 2, 1996),
App. D67

SOUTHWEST ONCOLOGY GROUP

Business review letters (Nov. 2,
1995), **App. C57**

SOUTHWEST ORTHOPEDIC SPECIALISTS (JUNE 10, 1997)

Business review letters, **App. C81**

SPECIAL COMMITTEE ON AGING, U.S. SENATE

Barriers to Generic Entry, Prepared
Statement of FTC Before (July
20, 2006), **App. E142**

SPECIALIZED SERVICES

Joint ventures among competitors to
provide new, **§ 16:9**

SPEECHES

Generally, **App. E et seq.**

See also topics beginning “Remarks”

Abandonment by Providence Health
& Services of plan to acquire
Spokane Cardiology and Health
Clinics Northwest, **App. E189**

“A ‘Check-Up’ of Selected Health
Care Activity at FTC” (Mar. 30,
2005), **App. E132**

“Anticompetitive Aspects of
Exclusive Dealing and Related
Practices,” **App. E88**

“Anticompetitive Pay-for-Delay
Settlements in the Pharmaceuti-
cal Industry; Why Consumers
and the Federal Government are
Paying Too Much for Prescrip-
tion Drugs,” **App. E169**

SPEECHES—Cont’d

“Antitrust, Accountable Care
Organizations, and the Promise
of Health Care Reform,” Edith
Ramirex, FTC Comm., **App.
E187**

“Antitrust Analysis of Hospital
Networks and Shared Services
Arrangements,” **App. E65**

“Antitrust Evaluation of Pay-for-
Delay Settlements: A Persistent
Quest for Balance,” **App. E196**

“Antitrust in Healthcare: A Keynote
Address,” **App. E124**

“Antitrust Issues in Settlement of
Pharmaceutical Patent
Disputes” (Part I - Nov. 3,
2000), **App. E102**

“Antitrust Issues in Settlement of
Pharmaceutical Patent
Disputes” (Part II - Nov. 3,
2000), **App. E103**

“Antitrust Issues Raised by Rural
Health Care Networks,” **App.
E80**

“A Stepwise Approach to Antitrust
Review of Horizontal Agree-
ments,” **App. E69**

Barriers to Generic Entry, Prepared
Statement of FTC Before
Special Committee on Aging,
U.S. Senate Concerning (July
20, 2006), **App. E142**

“Bending the Cost Curve: The View
from the Federal Trade Commis-
sion,” Julie Brill, FTC Comm.,
App. E206

Brill, Julie, prepared remarks before
North Carolina Bar Assoc., **App.
E198**

“Buyer Power Concerns and the
Aetna/Prudential Merger,” **App.
E91**

“Combination and Collaboration in
Health Care Markets: Antitrust
as a Constraint in a Time of
Change,” **App. E41**

“Comments on Nuts and Bolts of
Civil Antitrust Investigation by
DOJ Involving Healthcare
Industry,” **App. E66**

SPEECHES—Cont'd

- “Competition and Health Care: A Prescription for High-Quality, Affordable Care,” **App. E199**
- “Consummated Merger Challenges—The Past is Never Dead,” **App. E202**
- Credit Suisse 2018 Washington Perspectives Conference, remarks at, (Jan. 10, 2018), **App. E262**
- “Current Issues in Health Care Antitrust: Boycotts, Mergers, and Provider Networks,” **App. E54**
- “Current Issues in Health Care Antitrust Enforcement at FTC,” **App. E67**
- “Diagnosing Physician-Hospital Organizations,” **App. E125**
- “Efficiencies in Defense of Mergers: Eighteen Months After,” **App. E87**
- “Efficient Justifications for Hospital Mergers,” **App. E45**
- “Exclusionary Vertical Agreements,” **App. E85**
- “Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-c-k!,” **App. E141**
- “Guideposts in the Analysis: The Federal Trade Commission and U.S. Department of Justice, Antitrust Division Competitor Collaboration Guidelines,” **App. E92**
- “Health Care Guidelines and Associations—How Associations Can Work with the Department of Justice,” **App. E36**
- “Health Care Mergers: Will We Get Efficiencies Claims Right?,” **App. E79**
- “How Pay-for-Delay Settlements Make Consumers and the Federal Government Pay More for Much Needed Drugs,” **App. E168**
- “Importance of Competition and Antitrust Enforcement to Lower-

SPEECHES—Cont'd

- Cost, Higher-Quality Health Care,” **App. E172**
- “Integrated Joint Ventures,” **App. E57**
- “Joint Ventures in Evolving Health Care Markets,” **App. E34**
- Keynote remarks of Commissioner Rebecca Kelly Slaughter, Pharmaceutical Task Force Workshop, **App. E286**
- Leibowitz, Jon, prepared remarks regarding stereotypes before the AMA, **App. E182**
- Medco Health Solutions, FTC statement concerning acquisition by Express Scripts, **App. E203**
- “New Entry Into Hospital Competition” (May 24, 2005), **App. E134**
- “Oversight of the Antitrust Enforcement Agencies,” **App. E195**
- “Overview of Advisory Opinion Process at FTC,” **App. E74**
- “Patent Settlements, Patent Reform, and Mergers: Recent Developments in Pharmaceutical Antitrust,” **App. E190**
- “Preserving Our Hometown Independent Pharmacies Act of 2011,” **App. E201**
- Quality Health-Care Coalition Act, **App. E82, App. E89**
- Recent Developments in the FTC’s Antitrust Program for Health Care Markets”, **App. E51**
- Remarks of Mary Lou Steptoe, **App. E40**
- Remarks of Robert Pitofsky, Chairman, FTC, before Committee on Judiciary (Feb. 27, 1996), **App. E63** (Jul. 29, 1998), **App. E82**
- Respecting proposed regulations implementing the Affordable Care Act, **App. E188**
- “State Action Immunity for Health Care Collaboration after FTC v. Ticor,” **App. E39**

INDEX

SPEECHES—Cont’d

- Statement Of Commissioner
Christine S. Wilson in the matter
of HSR Premerger Notification,
App. E285
- “Statement to Negotiated Rulemak-
ing Committee on Shared Risk
Exception to Anti-Kickback
Statute,” **App. E77**
- “The One-Size-Fits-All Approach of
the Affordable Care Act,” **App.
E197**
- “The Rhetoric of Gun Jumping,”
remarks before Association of
Corporate Counsel Annual
Antitrust Seminar of Greater
New York Chapter (Nov. 10,
2005), **App. E138**
- “Thoughts on ‘Leveling the Playing
Field’ in Health Care Markets,”
App. E73
- “Twenty-Five Years of State
Antitrust Enforcement Applied
to Health Care,” **App. E96**
- “Use Your Time Wisely: Do’s and
Don’ts for Effective Advocacy
Before the Federal Trade Com-
mission,” **App. E100**
- Varney, Christine A., prepared
remarks before ABA/AHLA
Antitrust in Healthcare Confer-
ence, **App. E181**
- “Vertical Restraints with Horizontal
Consequences: Competitive
Effects of ‘Most Favored
Customer’ Clauses,” **App. E58**
- “Virtual Mergers of Hospitals: When
Does the Per Se Rule Apply?,”
App. E83

STAFF COMMENT

- North Carolina Senate Bill 743
give state action defense to UNC
healths collaborative activi-
ties, **App. D210**

STANDARD-SETTING PROGRAMS

- Under Section 1 of Sherman Act,
horizontal agreements, **§ 4:10**

STANDING

- As element of damage action, **§ 11:7**

ST. ANTHONY MEDICAL CENTER

- Business review letter, **App. C35**

STARK ANTI-REFERRAL LAWS

- Physician-owned facilities, **§ 18:2**

STARK COUNTY HEALTH CARE COALITION

- Business review letter, **App. C16**

STATE-ACTION DOCTRINE

- “License to Compete: Occupational
Licensing and the State Action
Doctrine,” prepared Statement
of FTC before the United States
Senate Committee on the Judi-
ciary (Feb. 2, 2016), **App. E249**

STATE-ACTION EXEMPTION

- From antitrust, **§ 9:7**
- Mergers, economic effects, **§ 15:6**
- Practitioner credentialing, **§ 13:6**

“STATE ACTION IMMUNITY FOR HEALTH CARE COLLABORATION AFTER FTC V. TICOR”

- (Speech), **App. E39**

STATE-ACTION PROTECTION

- Collaborative activity, FTC Staff
Advocacy letter to West Virginia
House of Delegates concerning
state-action protection (Mar. 9,
2016), **App. D183**

STATE ATTORNEYS GENERAL

- Protocol for coordination in merger
investigations between federal
enforcement agencies and state
attorneys general, **App. B3G**

STATEMENT

- Statement of Chair Lina M. Khan
Joined by Commissioner
Rebecca Kelly
- Slaughter and Commissioner
Alvaro M. Bedoya in the
Matter of Welsh, Carson
Anderson & Stowe (January 17,
2025), **App. N23**

STATEMENT 8

Provider-Controlled Networks (this index)

STATEMENT 9

Provider-Controlled Networks (this index)

STATEMENT OF COMMISSIONER

Christine S. Wilson, HSR Premerger Notification, **App. E285**

FTC and State of Rhode Island v. Lifespan Corporation and Care New England Health System, **App. E279**

Rebecca Kelly Slaughter, Contact Lens Rule, **App. E274**

Rohit Chopra, Review of the FTCs Pharmaceutical Merger Enforcement Program, **App. E275**

STATEMENT OF INTEREST

United States of America in the case of Duffy v. Yardi Systems, Inc. (3-1-24), **App. N27**

**STATEMENT REGARDING
PHYSICIAN AGREEMENTS
TO CONTROL MEDICAL
PREPAYMENT PLANS**

Advisory opinion, **App. D1**

**STATE UNIVERSITY OF NEW
YORK**

Certificate of public advantage application, FTC staff submission, **App. D206**

STATUTE OF LIMITATIONS

As damage action defense, § **11:10**

STATUTES

See also specific entries throughout this index

Antitrust Laws (this index)

STEERING

Diversification and
by other providers, § **17:14**
under Section 2 of Sherman Act,
§ **17:12**

ST. JOHN'S HEALTH SYSTEM

FTC staff advisory opinion to (Sept. 13, 2006), **App. D115**

**ST. LOUIS AREA BUSINESS
HEALTH COALITION**

Business review letter, **App. C25**

**SUBCOMMITTEE ON FEDERAL
FINANCIAL MANAGEMENT,
GOVERNMENT
INFORMATION, AND
INTERNATIONAL SECURITY**

“New Entry Into Hospital Competition” (May 24, 2005), **App. E134**

**SUBJECT MATTER
JURISDICTION**

Interstate commerce, § **2:2**

**SUBURBAN HEALTH
ORGANIZATION, INC.**

FTC staff advisory opinion to (March 28, 2006), **App. D113**

SUMMARY JUDGMENTS

Generally, § **12:1**

Dismissal, generally, § **12:1 to 12:3**

Failure to state a claim, motions to dismiss, § **12:2**

Motions, generally, § **12:3**

Motions to dismiss, § **12:1 to 12:3**

SUMMARY REPORT

FDA/FTC workshop on a competitive marketplace for biosimilars, **App. D208**

SUPERVISION

Georgia Board of Dentistry, FTC comments concerning proposed amendments to rules governing supervision of hygienists, **App. D136**

Georgia State Senate, FTC Advocacy letter to Hon. Valencia Seay concerning supervision of dental hygienists (Jan. 29, 2016), **App. D180**

Massachusetts House of Representatives, FTC letter concerning removal of supervision require-

INDEX

SUPERVISION—Cont'd

ment from nurse practitioners and nurse anesthesiologists (Jan. 17, 2014), **App. D162**

South Carolina House of Representatives, FTC advocacy letter concerning supervision of advanced practice nurses (Nov. 2, 2015), **App. D178**

SUPREME COURT DECISIONS

Federal Trade Commission (FTC), pharmaceutical patent settlements and Supreme Court, **App. E209**

“Lessons from the Commission’s Supreme Court Trifecta,” text of remarks of Jonathan Neuchterlein at American University Administrative Law Review Annual Symposium (Mar 20, 2015), **App. E239**

“Reflections on Supreme Court’s North Carolina Dental Decision and the FTC’s Campaign to Rein in State Action Immunity,” Maureen K. Ohlhausen, FTC Commissioner (Mar 31, 2015), **App. E240**

TARRANT COUNTY MEDICAL SOCIETY

Advisory opinion

July 11, 1984, **App. D13**

May 25, 1984, **App. D12**

TELECOMMUNICATIONS

Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D191**

TELEHEALTH SERVICES

Advocacy letter to Antitrust Division (Nov. 29, 2016), **App. C105**

Delaware Board of Speech/Language Pathologists, Audiologists, and Hearing Aid Dispensers, amendment to telecommunication and

TELEHEALTH SERVICES—Cont'd

telehealth regulations, FTC advocacy letter (Nov. 29, 2016), **App. D191**

FTC Advocacy letter to Alaska State Legislature concerning bill permitting (Mar. 25, 2016), **App. D184**

TEMPORARY RESTRAINING ORDER

Pursuant to Section 13(b) of the Federal Trade Commission Act, **App. N2**

TENNESSEE DEPARTMENT OF HEALTH

FTC Staff advocacy letter to Malaka Watson, Tennessee Department of Health, concerning cooperative agreements and certificates of public advantage (Sept. 24, 2015), **App. D176**

TERMINATIONS

Distributorship, under Section 1 of Sherman Act, vertical agreements, § 5:4

TESTIMONY

Division Director, Licensing & Certification at State of Maine

William Montejo, **App. N3**

Supporting LD 97

Division Director, Licensing & Certification at State of Maine, **App. N3**

TESTIMONY OF MARK BOTTI

“Competition in healthcare and certificate of need” before Georgia General Assembly (Feb. 23, 2007), **App. E145**

TEXAS HOUSE OF REPRESENTATIVES

Advisory opinions, Joint Negotiations by Physicians (May 13, 1999), **App. D85**

TEXAS STATE BOARD EXAMINERS

FTC Staff advocacy letter to Simone Salloum concerning proposed

**TEXAS STATE BOARD
EXAMINERS—Cont'd**
rules (Oct. 14, 2014), **App.
D166**

**TRADE REGULATION AND
CONSUMER LAW**

“Health Care Technology: Promoting
Competition and Protecting
Innovation,” Maureen K.
Ohlhausen, Commissioner of
FTC, before Connecticut Bar
Association Antitrust amp:
Trade Regulation and Consumer
Law Sections (Feb. 26, 2014),
App. E228

TRANSPLANT ASSOCIATES

Business review letter, **App. C29**

TRISTATE HEALTH PARTNERS

FTC staff opinion letter not to recom-
mend challenge of TriState’s
proposed program (Apr. 13,
2009), **App. D127**

**“TWENTY-FIVE YEARS OF
STATE ANTITRUST
ENFORCEMENT APPLIED TO
HEALTH CARE”**

(Speech), **App. E96**

**2006 MILTON HANDLER ANNUAL
ANTITRUST REVIEW**

Monopsony and the meaning of
consumer welfare, a closer look
at Weyerhaeuser (Dec. 7, 2006),
App. E144

**2007 ANTITRUST LAW FALL
FORUM**

Prepared slides of Jeffrey Schmidt,
Director, Bureau of Competi-
tion, before ABA Section
concerning “Critical Loss Anal-
ysis: A Merger Lawyer’s View”
(Nov. 16, 2007), **App. E157**

TYING ARRANGEMENTS

As vertical agreements under Section
1 of Sherman Act, § 5:6
Diversification resulting in, § 17:5

TYING ARRANGEMENTS—Cont'd

Hospital-physician exclusive
contracts as
generally, § 14:3
conditional sale of one service on
purchase of another, § 14:5
economic interest in sale of tied
product, § 14:8
effect on substantial amount of
interstate commerce, § 14:7
legitimate business justification,
§ 14:9
market power in the market for the
tying product, § 14:6
separate and distinct products,
§ 14:4

**UNC HEALTHS
COLLABORATIVE
ACTIVITIES**

FTC amicus brief
re Bystolic Antitrust Litigation,
App. D211
North Carolina Senate Bill 743
give state action defense to UNC
healths collaborative activi-
ties, **App. D210**

UNFAIR COMPETITION

Generally, § 7:1
Adoption of the Statement of
Enforcement Policy, Unfair
Methods of Competition Under
Section 5 of the FTC Act, **App.
E288**
Physician-owned facilities, § 18:2
Statement of enforcement principles
regarding “Unfair Methods of
Competition” under Section 5 of
FTC Act (Aug. 13, 2015), **App.
II**
Under Section 1 of Sherman Act,
horizontal agreements, § 4:9

UNFAIR TRADE PRACTICES

Federal Trade Commission, “Section
5: Principles of Navigation,”
Maureen K. Ohlhausen, Com-
missioner, before U.S. Chamber
of Commerce, Washington, DC
(July 25, 2013), **App. E220**

INDEX

UNITED HEALTH GROUP

Antitrust Division background of closing investigation of acquisition of Oxford Health Plans (Jul. 20, 2004), **App. E129**

UNITED STATES SENATE COMMITTEE

Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights Oversight of the Enforcement of the Antitrust Laws, **App. E287**

UNIVERSITY OF MICHIGAN

Federal Trade Commission (FTC), staff advisory opinion to the University of Michigan concerning the Non-Profit Institutions Act, **App. D131**

UNREASONABLY ANTICOMPETITIVE EFFECT ELEMENT

Anticompetitive Effect Element (this index)

URONET OF LOUISIANA, LLC

Advisory opinions (Jan. 23, 1996), **App. D61**

U.S. DEPARTMENT OF JUSTICE ANTITRUST DIVISION

Justice Department (United States Department of Justice, Antitrust Division) (this index)

U.S. DRUG DISTRIBUTION SYSTEM

Statement of FTC Bureau of Competition Deputy Director Rahul Rao on Lawsuit Against PBMs and the Role of Drug Manufacturers in Distorting Competition in the U.S Drug Distribution System (September 20, 2024), **App. N18**

“USE YOUR TIME WISELY: DO’S AND DON’TS FOR EFFECTIVE ADVOCACY BEFORE THE FEDERAL TRADE COMMISSION,”

(Speech), **App. E100**

U.S. V. AZHAA

“When Does a Group Purchasing Organization Become an Illegal Monopsonist?” prepared remarks before AHLA annual meeting (June 26, 2007), **App. E151**

UTAH SOCIETY OF ORAL AND MAXILLOFACIAL SURGEONS

Advisory opinion, **App. D14**

VALLEY BAPTIST MEDICAL CENTER

Advisory opinions (Sept. 19, 1996), **App. D70**

VALLEY GASTROENTEROLOGISTS

Business review letters (July 7, 1997), **App. C82**

VERMONT

U.S. Dept. of Justice statement on closing of Vermont home health investigation, **App. E139**

VERMONT PHYSICIANS CLINIC

Business review letters (July 30, 1997), **App. C83**

VERTICAL AGREEMENTS

“Exclusionary vertical agreements” (speech), **App. E85**

Mergers, § **15:29**

Provider-controlled contracting networks, multi-provider networks, § **20:13**

Sherman Act. Vertical Agreements (Section 1 of Sherman Act) (this index)

Vertical Price-Fixing Agreements (this index)

VERTICAL AGREEMENTS (SECTION 1 OF SHERMAN ACT)

Generally, § **5:1**

Distributorship terminations, § **5:4**

Dual distribution, § **5:5**

Exclusive dealing agreements, § **5:7**

**VERTICAL AGREEMENTS
(SECTION 1 OF SHERMAN
ACT)—Cont'd**

Price discrimination and commercial
bribery, § 5:9
Provider-controlled contracting
networks, multi-provider
networks, § 20:13
Reciprocal dealing agreements, § 5:8
Tying agreements, § 5:6
Vertical market-allocation agree-
ments, § 5:3
Vertical price-fixing agreements,
§ 5:2

VERTICAL INTEGRATION

As anticompetitive conduct under
Section 2 of Sherman Act,
§ 6:10

**VERTICALLY INTEGRATED
PHARMACY**

Specialty Generic Drugs
Growing Profit Center for Verti-
cally Integrated Pharmacy
Benefit Managers (January
14, 2025), App. N22

VERTICAL MERGERS

Generally, § 15:29
Under Section 7 of Clayton Act,
§ 8:14

**VERTICAL PRICE-FIXING
AGREEMENTS**

Exclusive contracts and, § 14:15
Under Section 1 of Sherman Act,
§ 5:2

VERTICAL RESTRAINTS

Most favored customer clauses,
speech entitled “Vertical
Restraints with Horizontal Con-
sequences: Competitive Effects
of ‘Most Favored Customer’
Clauses,” App. E58

VETERANS ADMINISTRATION

FTC advocacy letter, advanced
practice registered nurses
restrictions (July 25, 2016),
App. D188

**VIOLATIONS OF SECTION 1 OF
SHERMAN ACT**

Generally, § 3:2
Agreement element
generally, § 3:3
capacity to conspire, § 3:5
conspiracy in fact, § 3:6
nature of agreement, § 3:4
Anticompetitive purpose or intent
element
generally, § 3:7
intent and purpose in civil antitrust
cases, § 3:8
intent in criminal antitrust cases,
§ 3:9
purpose and intent in civil antitrust
cases, § 3:8
Collaborations among competitors,
§ 3:14
Unreasonably anticompetitive effect
element
generally, § 3:10
hybrid analyses, § 3:13
per se rule, § 3:12
rule of reason, § 3:11

**VIRGINIA DEPARTMENT OF
HEALTH**

FTC Staff advisory letter to Susan
Puglisi concerning cooperative
agreements (Sept. 17, 2015),
App. D175

**VIRGINIA HOUSE OF
DELEGATES**

Federal Trade Commission Office of
Policy Planning letter concern-
ing regulation of pharmaceutical
benefit managers (Oct. 2, 2006),
App. D116

VIRTUAL MERGERS

Single entity status and, § 15:4

**“VIRTUAL MERGERS OF
HOSPITALS: WHEN DOES
THE PER SE RULE APPLY?”**

(Speech), App. E83

VOLUNTARY

SELF-DISCLOSURES

New Safe Harbor Policy, Deputy
Attorney General Lisa O.

INDEX

VOLUNTARY

SELF-DISCLOSURES—Cont’d
Monaco, **App. B23**

WALES, DAVID P.

“Community Pharmacy Fairness Act of 2007,” Prepared Statement of FTC Before U.S. House of Representatives Judicial Committee Concerning HR 971 (Oct. 18, 2007), **App. E156**

“Examining Competition in Group Health Care,” Prepared Statement Before U.S. Senate Committee on Judiciary (Sept. 6, 2006), **App. E142A**

WARNING LETTER

Amphastar Pharmaceuticals Inc., **App.N35**

Covis Pharma GMBH, **App.N31**

Mylan Specialty LP, **App.N36**

Norton (Waterford) Limited, **App.N37**

Novartis Pharmaceuticals Corp, **App.N38**

Teva Branded Pharmaceutical Products R&D, Inc., **App.N33**

Teva Pharmaceutical Industries Ltd. c/o Teva, **App.N34**

WASHINGTON STATE MEDICAL ASSOCIATION

Business review letter, **App. C94**

WELLPOINT HEALTH NETWORKS, INC.

Anthem, Inc.’s acquisition of WellPoint Health Networks, Inc., Antitrust Division statement on closing of investigation of (March 9, 2004), **App. E128**

WESLEY HEALTH CENTER, INC.

Advisory opinions (Apr. 29, 1999), **App. D84**

WEST, DIANA

Business review letters (May 25, 2004), **App. C98**

WESTLAKE HEALTH CAMPUS ASSOCIATION

Business review letter, **App. C10**

WEST VIRGINIA HOUSE OF DELEGATES

Collaborative activity, FTC Staff Advocacy letter concerning state-action protection (Mar. 9, 2016), **App. D183**

WEST VIRGINIA SENATE

FTC Staff Advocacy letter concerning placing regulation of advanced practice registered nurse under State Board of Medicine and Osteopathy (Feb. 10, 2016), **App. D181**

WICHITA, KANSAS, CHAMBER OF COMMERCE

Advisory opinion, **App. D29**

WILLIAM J. SEITZ

FTC staff letter to Ohio State Senator Seitz concerning collective bargaining by home care providers (Feb. 14, 2008), **App. D123**

WILLIAM W. BACKUS HOSPITAL

Advisory opinions (June 11, 1996), **App. D64**

WILSON, CHRISTINE S.

“Bigger than Big Tech? The Need to Reform Our Health Care Markets Using Choice and Competition” (September 9, 2019), **App. E269**

Keynote remarks, Council for Affordable Health Coverage (January 16, 2020), **App. E370**

Need to establish privacy rules for Big Tech (May 18, 2020), **App. E372**

Statement, HSR Premerger Notification, **App. E285**

WORKSHOP SUMMARY

Pharmaceutical mergers, analysis examination

FTC-DOJ, **App. N4**

WRIGHT, JOSHUA D.

“Antitrust Analysis of Reverse Payments After Actavis: Three Questions and Proposed

WRIGHT, JOSHUA D.—Cont’d
Answers,” text of remarks
before the ABA Master Course
VII (Oct. 10, 2014), **App. E235**
“FTC v. Actavis and the Future of
Reverse Payment Cases,”
remarks of Joshua D. Wright,
Commissioner, FTC, before the
Concurrences Journal Annual
Dinner, New York, New York
(Sept. 26, 2013), **App. E224**
“Recent Antitrust Enforcement
Initiatives at the U.S. Federal
Trade Commission,” Joshua D.
Wright before the ABA Section
of International Law Confer-

WRIGHT, JOSHUA D.—Cont’d
ence, Beijing, China (Sept. 16,
2013), **App. E222**
“The FTC’s Role in Shaping
Antitrust Doctrine: Recent Suc-
cesses and Future Targets,”
Joshua D. Wright before the
2013 Georgetown Global
Antitrust Symposium Dinner,
Washington, D.C. (Sept. 24,
2013), **App. E223**
**YELLOWSTONE PHYSICIANS,
LLC**
Advisory opinions (May 14, 1997),
App. D75